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Cocrystals have drawn a lot of research interest in the last decade due to their 
potential to favorably alter the physicochemical and biopharmaceutical properties of 
active pharmaceutical ingredients. This dissertation focuses on the thermodynamic 
stability and solubility of pharmaceutical cocrystals. Specifically, the objectives are to;   
(i) investigate the influence of coformer properties such as solubility and ionization 
characteristics on cocrystal solubility and stability as a function of pH, (ii) to measure the 
thermodynamic solubility of metastable cocrystals, and study the solubility differences 
measured by kinetic and equilibrium methods, (iii) investigate the role of surfactants on 
the solubility and synthesis of cocrystals, (iv) investigate the solid state phase 
transformation of reactants to cocrystals and the factors that influence the reaction 
kinetics and, (v) provide models that enable the prediction of cocrystal formation by 
calculating the free energy of formation for a solid to solid transformation of reactants to 
cocrystals.  
Cocrystal solubilities were measured directly when cocrystals were 
thermodynamically stable, while solubilities were calculated from eutectic concentration 
measurements when cocrystals were of higher solubility than its components. Cocrystal 
solubility was highly dependent on coformer solubilities for gabapentin-lactam and 
lamotrigine cocrystals. It was found that melting point is not a good indicator of cocrystal 
solubility as solute-solvent interactions quantified by the activity coefficient play a huge 
role in the observed solubility.  Similar to salts, cocrystals also exhibit pHmax, however 
the salts and cocrystals have different dependencies on the parameters that govern the 
value of pHmax.  It is also shown that cocrystals could provide solubility advantage over 
salts as lamotrigine-nicotinamide cocrystal hydrate has about 6 fold higher solubility 
relative to lamotrigine-saccharin salt.   
In the case of mixtures of solid reactants, it was observed that cocrystals can form 
spontaneously when the reactants are in physical contact and that temperature, relative 
humidity, and disorder in the reactants caused by mechanical stress such as milling can 
enhance the reaction rates. Prediction of spontaneous cocrystal formation was 
investigated by developing models to calculate the Gibbs free energy of formation. 
Thermal behavior of cocrystal reactants was investigated by calorimetry and the 
interaction between the reactants is explained by investigating the heats of mixing in the 
melt. These principles are applied on cocrystals that are divided into two categories; 
(i) Where the cocrystal melting point is between that of its reactants and, (ii) where the 
cocrystal melting point is below that of its components. Generalized equations were 
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developed that enable the calculation of Gibbs free energy of formation from fusion 




        CHAPTER 1 
       INTRODUCTION 
 
This chapter introduces cocrystals in the context of their design and synthesis, 
physicochemical properties, the current understanding of solid state and solution 
chemistry, and the role additives can play in cocrystal research. Cocrystal solid-solution 
equilibria that describe solubility product behavior are presented. Mechanisms of 
cocrystal formation are discussed with emphasis on reaction crystallization method which 
incorporates the solubility product behavior. Reaction crystallization method and 
solubility product behavior is applied in the synthesis and solubility assessment of 
cocrystals presented in chapters 2 and 3.  A few case studies are presented from published 
literature where cocrystals have shown favorable pharmaceutical properties such as 
solubility, dissolution and stability enhancements. The model compounds used are 
mentioned where applicable, however a detailed description of compounds can be found 
in relevant chapters.  The chapter concludes with the key questions this research will 
address, statement of dissertation research and brief summaries of the contents in the 
research chapters. 
 
What are Cocrystals? 
Cocrystals are a single homogenous crystalline phase containing multiple distinct 
molecules often linked by hydrogen bonds. Cocrystals are not physical blends of pure 
components.  Cocrystal physical and chemical properties are a function of unique solid-
state arrangement of the molecules in the crystal lattice.  Cocrystals are able to alter the 
physicochemical properties of active drug substances by combining drugs and coformers 
in the same crystal structure thereby altering solid-state properties and solution phase 
behavior without modifying the active’s chemical structure. Properties that have a basis 
in the underlying crystal structure are therefore affected when a cocrystal is formed.1-3  
This ability of cocrystals to alter material properties of pharmaceutical relevance using 
crystal engineering principles and strategies has motivated the discovery of a large 
number of pharmaceutical cocrystals for drug development.4-8  One of the most 
commonly faced challenge in drug development is the poor aqueous solubility of the 
active, which often results in dissolution rate limited bioavailability. Lipinski reported 
that between 1987 and 1994, nearly one-third of newly synthesized compounds in 
academic laboratories had solubilities less than 20 μg/mL.9  Serajuddin reports that one-
third of newly synthesized compounds have aqueous solubilities less than 10 μg/mL, and 
another one-third have aqueous solubilities between 10 and 100 μg/mL.10  Cocrystals 
have been proven useful in addressing this issue by modulating the aqueous solubility of 
the drug as well as tailor the solubility based on coformer solubility and ionization 
properties.11, 12  Depending on the desired pharmacokinetic effect, alternative solid forms 
such as salts, cocrystals and prodrugs can also be used to prolong the release of active 
compounds. Controlling release kinetics is of importance in the case of drugs exhibiting 
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short half lives, large Cmax values or toxicity due to high solubility as well as for taste 
masking.13-16 Cocrystals are unique relative to current options for altering 
physicochemical drug properties in pharmaceutical development because of the number 
of suitable drugs and possible coformers as well as the large number of intramolecular 
associations and supramolecular structures that can lead to cocrystal formation. 
Cocrystals provide a unique advantage over other alternative solid forms in 
altering physico-chemical properties. For example, salts are commonly used to alter 
solubility, stability, mechanical properties of the API but only drugs with ionizable 
groups are candidates for salt formation and successful salt formation is in part a function 
of the drug pKa value(s).  Amorphous solids can significantly change the solubility of a 
drug by eliminating crystal lattice energy as a barrier to solubilization,17 however 
thermodynamic stability issues limit their applications.  Cocrystals expand the options for 
drugs with challenging physicochemical properties by offering a large number of suitable 
coformers to change solution and solid-state chemistry.  Furthermore cocrystals afford 
the preferred solid-state stability of a crystalline solid form for drug delivery.  An 
overview of the classification and nomenclature of solid forms relevant to pharmaceutical 
development is presented in Figure 1.1 which, includes multi-component crystalline 
forms and cocrystals. 
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Figure 1.1: The range of single crystalline forms that are possible for an API: (a) pure 
API; (b) polymorph of pure API; (c) clathrate hydrate/solvate of API; (d) hydrate/solvate 
of API; (e) salt of API; (f) pharmaceutical cocrystal. Salts and cocrystals can also form 
hydrates, solvates, and polymorphs.18 
 
Design Elements of Cocrystals 
 
Hydrogen bonds play an important role in organic materials due to their ability to 
form weak intermolecular interactions. The products of these intermolecular interactions 
are hydrogen-bonded molecular aggregates, defined by connectivity patterns arising from 
hydrogen.  Such aggregates could be formed in solution or in solid state.19  As a result of 
molecular recognition phenomenon, hydrogen bonded supramolecular assemblies are 
formed. These supramolecular assemblies could either be single component crystals or 
multiple component cocrystals. The types of hydrogen-bond synthons and molecular 
aggregates likely to form between cocrystals components can be predicted by several 
general rules developed by Etter.1, 20 There are three very useful rules, commonly referred 
to as hydrogen bond rules that reflect molecular recognition,19 these are, 
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 All acidic hydrogen available in a molecule will be used in hydrogen bonding in the 
crystal structure of that compound. 
 All good acceptors will be used in hydrogen bonding when there are available 
hydrogen bond donors. 
 The best hydrogen bond donor and the best hydrogen bond acceptor will 
preferentially form hydrogen bonds to one another. 
As a result of formation of hydrogen bonds between molecules, synthons are formed.  
Some examples of hydrogen bonded synthons are shown in the figure below. 
O
 
Figure 1.2: Common synthons in the supra molecular assemblies.  
 
Synthons are classified as homosynthons and heterosynthons depending on the nature 
of the interacting functional groups in molecules. Homosynthons are formed by the 
interaction of similar functional groups while heterosynthons are formed by the 
interaction of different functional groups. These interacting functional groups form 
synthons through hydrogen bond formation. The term homosynthons or heterosynthons 
































entities. A homosynthon can be formed in a multi component cocrystal whereas a 
heterosynthon can be formed in a single component crystal. Examples of homosynthons 
and heterosynthons are shown in Figure 1.3. 
    
     amide-amide homosynthon     acid-amide heterosynthon 
Figure 1.3: Example of homosynthon and heterosynthon. 
 
Depending on the nature of the interacting molecules the terms homomers or 
heteromers is used to describe the molecular aggregate formed. If the interacting 
molecules are the same, then the resulting aggregate is a homomer, whereas a heteromer 
is said to be formed when the result is a multi component cocrystal. Cocrystals are a 
result of hydrogen bond formation between neutral molecules of two or more different 
components. The term cocrystal is generally used when it is formed from components 
which in their pure states are solids at room temperature.21 While these rules are good 
general considerations they do not predict crystal structure, molecules capable of 
cocrystallizing with each other, conditions that promote cocrystallization, or the 
properties of cocrystals that might form.22  Exceptions to these guidelines often occur due 
to competition of multiple hydrogen bonding, dipole, or ionic sites as well as steric or 
conformational limitations. Considerations of van der Waals interactions and 
stereochemistry of the components are also relevant for cocrystal design and coformer 
selection.22  Symmetry elements and conformational energies of molecules play essential 
roles in determining crystal structures. The formation of stable crystal structures is 
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additionally based on minimizing electrostatic energies (e.g. bond or molecular dipoles) 
and minimizing free volume (i.e. maximizing density). A search of the Cambridge 
Structural Database (CSD) showed that molecules containing carboxamide moieties form 
multicomponent crystal forms with carboxylic acids via synthon. Zaworotko and 
coworkers published a CSD survey of compounds containing primary amides and 
carboxylic acid groups that suggested that 47% of the structures formed acid ··· amide 




23 Recent analysis of coformers published in the CSD indicated 
that shape, polarity, and available synthons were key parameters for designing cocrystals, 
however the number of hydrogen bond donors and acceptor was not statistically 
significant.24  Together all these structural considerations of the crystalline state influence 
the design and stability of cocrystals.  
 
Cocrystal Synthesis 
 Currently the most established methods for cocrystal formation are solvo-thermal 
and mechanical techniques. In solvo-thermal cocrystal synthesis, stoichiometric ratios of 
reactants are dissolved in a solvent of choice and supersaturation is achieved either 
through a temperature difference or through evaporation of the solvent. In mechanical 
cocrystal synthesis, stoichiometric ratios of reactants are mechanically agitated (e.g. by 
grinding in a mill) to induce phase transformations from a physical mixture into 
cocrystal.7, 25-27  Drops of solvent, which are considered plasticizers, have been shown to 
impact the crystallization outcome.28-31 Mechanical methods are often favored due to 
their speed, procedural simplicity, and potential for green chemistry. 
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 While grinding experiments are attractive because of small requisite quantities of 
components and rapid synthesis. Some limitations include the difficulty of readily 
discerning the formation mechanism or pathway, the chemical stability of components 
subjected to high kinetic energy process, purity of products (i.e. extent of transformation), 
empirical nature, and challenges regarding scalability. Solvo-thermal techniques often 
rely on empirical choices of solvent, temperature conditions, and molar ratio of reactants.  
There is a risk of crystallizing one or more undesirable phases if conditions are chosen 
such that cocrystal is not the thermodynamically stable phase.  Mechanical techniques are 
also subject to empirically selected conditions (such as selection of solvent drop and 
grinding time), but the main challenges include process scalability, reactant stability 
during mechanically/thermally energetic processes, and extent of transformation. 
Reaction crystallization is an emerging solution-mediated cocrystal synthesis 
method that complements the other more established methods.32 The reaction 
crystallization method (RCM) relies on creating supersaturation through cocrystal 
solution phase chemistry. The solubility product behavior of cocrystals described by 
Nehm and Rodríguez-Hornedo et al. provided the basis for their development of RCM 
wherein cocrystal had lowest solubility, was thermodynamically stable, in solutions 
containing excess of one of the cocrystal components.33 Cocrystal solubility is described 
by solubility product behavior, which indicates that cocrystal solubility decreases as 
coformer concentration increases.33, 34  Cocrystal solubility is decreased below that of the 
drug by adding coformer at or near the coformer solubility. Therefore, conditions are 
chosen to maximize the likelihood of obtaining cocrystal by operating in a region of the 
phase diagram where cocrystal is least soluble and maximum supersaturation with respect 
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to the cocrystalline solid phase can be generated (Figure 1.4).  Supersaturation affects the 
nucleation rate, high supersaturation achievable in the reaction crystallization leads to fast 
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No is the number of molecules of the crystallizing phase per unit volume 
ν is the frequency of molecular transport at the nucleus-liquid interface 
υ is the molecular volume of the crystallizing phase 
kb is the Boltzmann constant 
γ is the interfacial energy between the crystal nuclei and supersaturated solution 
T is the temperature 
 
Mechanisms of Cocrystal Formation 
Phase Diagram - Reaction Crystallization Method (RCM) 
 The driving force for crystallization is the difference between the chemical potential at  
a supersaturated state (liquid) and at equilibrium. At the solubility, the equilibrium phases 
have equal molar free energies or chemical potentials.  In the case of cocrystals this is the 
sum of the molar free energies or chemical potentials of each cocrystal component.  The 
molar free energy of a cocrystal AmBn in equilibrium with solution phase is given by, 
m n
L L
A B solution A B A BG G mG nG m n      
i
 (1.1) 
The activity of each component ai is defined as, 
o
i i RT ln a     (1.2) 
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where oi is the chemical potential of the reference state for i. Combining equations (1.1) 
and (1.2) gives, 
m nA B solution A B
G G RT(mln a n ln a )      
m nA B m n
A B
G







A B(a ) (a )
n  is the solubility product, Ksp of the cocrystal. Figure 1.4 shows the phase 
diagram that explains the cocrystal formation pathways and stability domains. A is the 
drug and B is the ligand (cocrystal former). Cocrystals follows the solubility product 
(Ksp), i.e., with increasing ligand concentration, higher supersaturation with respect to the 
cocrystal is generated and the cocrystal precipitates out of the solution.35 The transition 
concentration at which the concentration of cocrystal is equal to the concentration of the 
drug is known as the ligand transition concentration shown in Figure 1.4 as Btr. At the 
ligand transition concentration the drug and the cocrystal solid phases are in equilibrium 
with each other. Details of all the four regions of the phase diagram are described below. 
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Figure 1.4: Solubility phase diagram for crystal A and cocrystal AB, showing the 
transition concentration, [B]tr. 
 
Region I: Supersaturated with respect to A and undersaturated with respect to AB, 
therefore in region I crystalline form AB will transform to crystalline form A. 
Region II: Supersaturated with respect to A and AB and the thermodynamically more 
stable phase AB will precipitate as the stable solid phase. 
Region III: Undersaturated with respect to both A and AB resulting in a solution. 
Region IV: Supersaturated with respect to AB and undersaturated with respect to A and 
crystalline form A will transform to cocrystalline form AB.35 
The transition concentration is also referred as a eutectic point, this is because at 
the transition concentration Gibbs phase rule constraint is invoked. According to the 
Gibbs phase rule at constant pressure, P + F = C+1, the term 1 represents the 
temperature variable. 
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Phases (P): For a cocrystal system, at the eutectic point (transition concentration), there 
are three phases, solid which is composed of two separate homogeneous solid phases 
(cocrystal and drug) and liquid (solution), together constituting three phases.   
Components (C): Coformer, Drug and Solvent 
Thus, P = 3 and C = 3 resulting in F=1.  This implies that the eutectic concentration is 
temperature dependent and when the temperature is constant, there are zero degrees of 
freedom.  This is compared with the more widely used eutectic point for a melt at 
constant pressure below where, 
Phases (P): Solid and liquid, where solid is composed of A and B components.  Thus 
there are 3 phases, namely Solid A, solid B and melt (liquid). 
Components(C): A and B. 
Thus, when P = 3 and C = 2 the resulting F = 0, this type of solid-liquid eutectic 
is rigidly defined by the temperature and can be achieved only at a particular temperature 
when the pressure is constant.  Multiple eutectic points can exist depending on what solid 
phases coexist at equilibrium.  In the case of a cocrystal AB with no other stoichiometries 
or polymorphs, two eutectics exist; the first is between solid drug, cocrystal, and solution, 




Figure 1.5: (a) Flowchart of method used to establish the invariant point and determine 
equilibrium drug and coformer eutectic concentrations, (b) Schematic phase solubility 
diagram that illustrates two pathways to the eutectic point (marked X).11 
 
 
Figure 1.5 shows the schematic pathway to determine the solubility of cocrystal 
via the eutectic point.  The intersection of cocrystal and drug solubilities is the eutectic 
between solid drug, cocrystal, and solution. From the concentrations of drug and 
coformer at the eutectic, the cocrystal solubility product Ksp can be calculated. 
 
Eutectic and Vapor Phase Mediated Cocrystal Formation 
Cocrystal formation via cogrinding of solid reactants has been explained by 
eutectic formation when the reactants are milled together.36, 37 Milling the reactants raises 
the mill temperature significantly above room temperature, which can cause the reactants 
to melt and initiate the reaction.  However, the temperature at which the reactants melt is 
lower than the melting temperature of the individual reactants. Eutectic melt-mediated 
cocrystal formation at room temperature has been reported for benzophenone and 
diphenylamine.36 Similar behavior has been shown for cocrystals of CBZ with carboxylic 
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acids at temperatures above 85°C.37 Solid-vapor interactions due to sublimation of 
reactants have also been reported to form cocrystals.38-40 
 
Deliquescence Mediated Cocrystallization 
It has been shown that cocrystal formation can occur during storage by vapor 
sorption of reactant components.41 Phase transformations of APIs in the presence of 
moisture sorbed by hygroscopic materials are well known and are suggested to proceed 
through a solution mediated process.42 It is reasonable to expect solution mediated phase 
transformation of drug to cocrystal in solid mixtures of cocrystal components with 
deliquescent materials.  
 Deliquescent and hygroscopic cocrystal components or excipients have been 
shown to facilitate solution-mediated formation of cocrystals.  Deliquescent excipients 
including sucrose, fructose, and citric acid led to cocrystal formation for various 
components.43 The mechanism indicated consisted of deliquescence of the excipient, 
followed by dissolution of the cocrystal components in the sorbed moisture, then 
subsequent crystallization of cocrystal from solution.  In this solution mediated 
mechanism supersaturation with respect to cocrystal was generated from dissolution of 
components in the sorbed moisture.  Cocrystal nucleation was observed near the surface 
of undissolved carbamazepine crystals presumably due to the high drug concentrations at 
this boundary producing the greatest supersaturation in the concentrated 
nicotinamide/sucrose solution. Cocrystal formation in solid blends of cocrystal 
components and deliquescent materials involves 4 essential processes: (i) moisture 
sorption by deliquescent material (ii) dissolution of cocrystal components in the moisture 
sorbed by deliquescent material (iii) supersaturation with respect to cocrystal and (iv) 
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crystallization of cocrystal. Thus the rate of cocrystal formation in solid blends 
containing deliquescent materials will depend on the rate of moisture sorption, 
dissolution of reactants and supersaturation. The driving force for moisture sorption 
depends on the difference between the relative humidity of the surroundings (RHs) to 




Less common synthetic methods include melt processes such as the Kofler mixed 
fusion method and differential scanning calorimetry (DSC) of components in physical 
blends.  Kofler’s methods have been used to efficiently determine the formation and 
phase behavior of many multicomponent crystals and their polymorphs. A recent 
example is the work of Berry et al. who screened for cocrystals of seven drugs with 
nicotinamide and determined the structures of three novel cocrystals including that of 
R/S-ibuprofen-nicotinamide.45 DSC and hot stage microscopy are also shown as an 
efficient thermal method for screening cocrystals of carbamazepine, theophylline, 
caffeine, lamotrigine and sulfamethazine.37, 46 
 
Solubility and Solution Chemistry of Cocrystals 
 
Cocrystal Solution Chemistry 
 
Cocrystal solubilities have been commonly expressed using a variety of 
equilibrium and kinetic measurements. Kinetic solubility measurements reported are 
typically powder dissolution or intrinsic rotating disk dissolution. Both equilibrium and 
kinetic experiments present valuable information on the solution properties and 
performance of cocrystals relative to the components. Crystallization of other drug forms 
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can occur in kinetic studies particularly when cocrystal is highly soluble relative to the 
components. 
The true stoichiometric solubility of a cocrystal is often difficult to measure 
directly because of purity issues, unknown or complex solubility phase behavior, and 
potential transformations to other solid forms such as components or other cocrystal 
stoichiometries or solvates. The measurement of an equilibrium or steady state drug 
concentration from a cocrystal placed in solution does not always reflect the actual 
stoichiometric solubility depending on the final solid phase(s) that persist at equilibrium 
point. Isolation and analysis of solid phase(s) is critical in describing solubility because 
the final solid form is associated with the measured concentration(s). Only when the 
initial cocrystal form is observed as the single solid phase after equilibration with pure 
solvent are the equilibrium concentrations descriptive of the true stoichiometric solubility.  
When a solid phase other than the starting cocrystal is observed, the corresponding steady 
state drug concentration is not the true cocrystal solubility. In these instances both 
component concentrations should be recorded to best describe solubility behavior of the 
solid phase(s) in equilibrium with the solution. If one of the stable equilibrium solid 
phases is a cocrystal of known stoichiometry, the Ksp can be calculated and reported to 
describe the thermodynamic cocrystal solubility. 
 Cocrystal solution phase behavior was first investigated by Higuchi, Connors, and  
coworkers, though their focus was on solution complexation between cocrystal 
components.47-49  Their experiments showed that cocrystals adhered to solubility product 
behavior, where increasing coformer concentration led to decreasing drug concentration 
at equilibrium. The theoretical framework developed for cocrystal solubility allows for 
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rational selection of solvent and solute concentrations to control and optimize 
cocrystallization processes. RCM is a scalable technique, amenable to both large and 
small scales.  RCM has been successfully used in addition to other methods to screen for 
carbamazepine and piroxicam cocrystals,4, 5 and can be applied with equal success in 
green solvents such as water. A recent screening of twenty-seven carbamazepine 
cocrystals by four different methods including RCM identified all of the forms generated 
by grinding of components were also found by at least one of the other solution methods.5   
Cocrystals are often selected for their high solubilities relative to the drug.  Cocrystals 
that are highly soluble relative to drug can transform, sometimes very rapidly, to the less 
soluble crystalline drug. Equilibrium solubilities that use drug concentration as a measure 
of cocrystal solubility are confounded by such conversions, which can lead to 
underestimation of true cocrystal solubilities. Kinetic solubility measurements are limited 
by the kinetics of transformation and depend highly on experimental conditions, which 
are often empirically selected. This dissertation establishes the fundamental solution 
behavior of cocrystals wherein cocrystal solubility is shown to be highly dependent on 
the nature of its components. Lower solubility coformers are shown to decrease cocrystal 
solubility and corresponding drug concentrations, while non-ionizable compounds can 
exhibit pH dependent solubility when ionizable coformers are selected. Also this work 
demonstrates that thermodynamic methods to evaluate solubility can yield large 
discrepancies with values estimated from kinetic methods. These methods are derived 
from the mathematical models that describe cocrystal solubility in terms of cocrystal 
solubility product (Ksp), solution complexation constant (K11) and the pH dependent 
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solubility behavior introduced by Nehm et al.33  The chemical equilibria that describe 








A B AB          (1.4) 
where Ksp and K11 are the cocrystal solubility product and the complexation constant for 
a 1:1 solution complex between A and B.  Ksp and K11 are given by 





           (1.6) 
under the assumption of dilute conditions where activities are approximated by 
concentrations. By mass balance, where [A]T and [B]T are the total analytical 
concentrations of A and B, 







  11 sp          (1.8) 
Equation (1.8) is an expression of the cocrystal solubility (in terms of drug concentration) 
as a function of the coformer concentration at equilibrium. Figure 1.6 shows the 
solubility of a 1:1 cocrystal of carbamazepine and nicotinamide (CBZ-NCT) in three 
organic solvents. Figure 1.6 shows that cocrystal solubility decreases as a function of 
coformer concentration.   
 18
 
Figure 1.6: Solubility of 1:1 CBZ-NCT cocrystal at 25 °C as a function of total NCT 
concentration in ethanol, 2-propanol, and ethyl acetate.33  The solid lines represent the 
predicted solubility according to Equation (1.8). Filled symbols are experimental 
cocrystal solubility values in (■) ethanol, (▲) 2-propanol, and (●) ethyl acetate. 
 
For a 1:1 cocrystal, the cocrystal solubility in solutions containing stoichiometric solution 
concentrations of A and B, SAB, is given by 
AB T TS [A] [B]   (1.9) 
AB spS K  (1.10) 
if we assume K11Ksp << SAB. 
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Cocrystal Solubility Dependence on Coformer Solubility 
Solid state properties are often considered as a basis to predict solubilities, while 
solution phase contributions are not weighed upon. When solubility is limited by the 
strength of the crystal lattice, solubility is dependent on melting of the solid solute given 








   
 
            (1.11) 
where χideal is the ideal solubility expressed as mole fraction, R is the gas constant, T is 
the reference temperature, Tm and Hm are melting temperature and enthalpy in Kelvin.  
Equation (1.11) assumes that the heat capacity change upon melting is negligible, and 
that solubility is a property of the solid solute only and is not solvent dependent.  Such a 
behavior only applies to ideal solutions or to different solid state forms of the same 
chemical components such as polymorphs.  Solids with different chemical composition 
can exhibit an inverse proportionality between solubility and melting point when 
solvation energy changes are parallel to lattice energy changes.  However, melting point 
is a poor indicator of observed solubility due to the fact that solubility is often limited by 
solvation and not by lattice energy alone. The observed aqueous solubilities are highly 
dependent on the solvation barrier (hydrophobicity) due to solute solvent interactions.  
Coformer solubility has also been shown to influence cocrystal solubility. This is due to 
coformer altering the solvation barrier for the cocrystal Figure 1.7.50 
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Figure 1.7: The ratio of coformer to drug solubility plotted against the cocrystal solubility 
ratio (filled circles) and the ratio of coformer to drug eutectic concentrations (open 
circles).11 All aqueous samples are shown in red. Several cocrystals with the same 
coformers are labeled.  
 
Figure 1.7 shows the cocrystal to drug solubility ratio against the coformer to drug 
solubility ratio for several cocrystals. The solubilities of twenty-five cocrystals were 
ranked according to their solubility advantage over drug.11  The cocrystals were various 
combinations of three drugs (carbamazepine, theophylline, and caffeine) and seven 
coformers (malonic acid, nicotinamide, salicylic acid, saccharin, succinic acid, glutaric 
acid, and oxalic acid) in four solvents (water, isopropyl alcohol, methanol, and ethyl 
acetate). The measured cocrystal solubilities ranged from 0.1 to over 100-fold their 
respective drug solubilities and the coformer solubilities spanned several orders of 
magnitude, from 10-2 m to 101 m. The dependence was demonstrated to be linear, where 
larger coformer to drug solubility ratios resulted in cocrystals that were more soluble 
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relative to the drug.  This work demonstrated that cocrystal solubility enhancement could 
be rationally selected based on knowledge of the coformer solubility. 
 
Role of Additives in Cocrystal Research 
 Role of differential solubilization by sodium lauryl sulfate (SLS) on cocrystal 
solubility is recently demonstrated by Huang and Rodríguez. Cocrystal and drug show 
different solubility dependencies as a function of SLS concentration, resulting in a critical 
stabilization concentration (CSC) with respect to SLS beyond which cocrystal is less 
soluble and thermodynamically stable solid phase (Figure 1.8).51  
 
Figure 1.8: Schematic representation of the cocrystal (RHA) and drug (R) solubility with 
respect to the total surfactant concentration.  The differential solubilization of cocrystal 
and drug results in the intersection of solubility curves yielding a CSC (critical 
stabilization concentration) at which both cocrystal and drug are in equilibrium with the 
solution.   
 
Surfactants are important additives that have range of pharmaceutical applications 
such as solubilizers, emulsifiers, detergents, foaming agents, lubricants, etc.52-54 
Dissolution of celecoxib-nicotinamide cocrystal into aqueous media (pH 6.5) containing 
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1% SLS demonstrated that a 5-minute “pre-suspension” process could lead to variable 
dissolution rates based on extent of transformation from cocrystal to drug, which could 
compromise a potential dosage form. This implies that excipients such as SLS can affect 
which solid forms are favorable in solution as well as the kinetics of transformation to 
those solid forms. Remenar et al. investigated the influence of SLS and polymer 
polyvinylpyrollidone (PVP) mixtures on dissolution and phase stability of a 1:1 cocrystal 
of celecoxib and nicotinamide.8 Celecoxib-nicotinamide cocrystal was suspended in 
aqueous media with varying pH, ionic strength and SLS concentration. Cocrystal was 
found to transform to drug in all cases, but in the presence of SLS transformation resulted 
to different polymorphs of celecoxib.  Thus, mixtures of cocrystal, PVP K-30, and SLS 
were formulated to inhibit the transformation to less soluble drug. Dissolution of 
cocrystal, PVP, and SLS mixtures into aqueous media (pH 6.5) containing 1% SLS 
exhibited dissolution rates comparable to amorphous form/PVP mixtures in the same 
media. This investigation demonstrated that solution conditions (such as pH) and 
excipients (PVP, SLS) affected cocrystal solution phase behavior, although further 
investigation is needed to understand the mechanisms involved in these phase transitions.  
One limitation of this work is the lack of quantitative theoretical treatment and 
mechanistic understanding of excipient effects on cocrystal solution chemistry that can be 




Properties of Pharmaceutical Cocrystals: A Few Case Studies 
Solubility is a critical property of pharmaceutical materials, since an active must 
be in solution to be absorbed.  Solubility is defined by thermodynamic equilibrium of the 
solid phase of a solute with its solution. The structure and properties of cocrystals are 
distinct from that of their individual components. Cocrystals have been shown to change 
the hygroscopicity, melt temperature, chemical and thermal stability, solubility and 
dissolution rate, bioavailability, hydrate/solvate formation as well as mechanical 
properties.  Any chemical or physical properties that are a function of the supramolecular 
structure are potentially modified by cocrystal formation. The design and formation of a 
cocrystal to change a particular physicochemical drug property will likely change 
additional properties since the structure and supramolecular chemistry are not exclusive 
to any one physicochemical property.  If designing a cocrystal for improved drug 
solubility one should anticipate changes to many other properties, such as possibly the 
crystal density or habit, that are dependent on supramolecular structure.  A few case 
studies are presented below where increased bioavailability or maximum plasma 
concentration (Cmax) has been demonstrated for several drug substances. 
 
Itraconazole Cocrystal 
Itraconazole, an antifungal agent with low solubility (~1ng/ml) in its free base 
form, has been reported to form several cocrystals with 1, 4 dicarboxylic acids.  All of the 
cocrystals demonstrated an enhanced dissolution profile as compared with itraconazole 
free base.  In some cases the dissolution profiles of the cocrystals approached that of 
amorphous itraconazole.55 The three cocrystals studied achieved sustained (>400 minutes) 
dissolution concentrations from 4 to 20-fold of the crystalline itraconazole level.55  
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Remenar also showed for the celecoxib-nicotinamide cocrystal that formulation with 
surfactant (SDS) and polymer (PVP) provided similar dissolution rates as amorphous 
blends of drug and PVP. Here the cocrystal formulation produced an 
amorphous/crystalline blend with small particulates (~380nm) of a metastable drug 
polymorph (celecoxib IV).8  This study demonstrated formulation methods to exploit the 
high cocrystal solubility relative to celecoxib to design rapidly dissolving drug products. 
 
API-Glutaric Acid Cocrystal 
2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide, which is a 
sodium channel blocker with low dissolution rate and bioavailability. This API belongs to 
BCS class II (low solubility-high permeability). Traditional methods of forming salts and 
amorphous material failed to produce a viable solid form for continued development.  
However, cocrystal with glutaric acid resulted in higher bioavailability when tested in 
dogs. These in vivo studies were in agreement with aqueous rotating disk intrinsic 
dissolution results that indicated significant improvement for the cocrystal (~18-fold 
increase) over the pure drug at 37˚C.56 
 
Fluoxetine·HCl Cocrystals 
Another example of altered dissolution was observed for three cocrystals of 
fluoxetine HCl, an active ingredient to treat depression. This is an interesting case as the 
researchers designed the cocrystals by combining a carboxylic acid with the hydrochloric 
acid (HCl) salt of fluoxetine, generating three novel cocrystals of salts with three 
different acid coformers. The individual cocrystals were found to have dissolution rates 
above, below and comparable to the salt form of the drug.57 Using different ligands, 
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dissolution rates could be controlled.  This is due to the ligand properties such as pKa 
(pH-solubility profile) and aqueous solubility. Cocrystals of different ligands also have 
different lattice energies which may govern their solubility and dissolution behavior.57 
 
AMG 517 – Sorbic Acid Cocrystal 
In a recent study, a new chemical entity inadvertently formed a cocrystal with one 
of the formulation components. AMG 517 is a poorly soluble VR1 (vanilloid receptor 1) 
antagonist. In animal studies good exposure of the drug was seen from a 10% (w/v) 
Pluronic F108 in OraPlus suspension.  This was due to the fact that the drug had formed a 
cocrystal with sorbic acid, a preservative in Ora Plus.58 This also emphasizes the 
importance to understand the possibility of unintentional cocrystallization. Such 
uncontrolled events can occur during development and/or storage depending on the 
reaction kinetics. Thus a molecular level understanding of cocrystallization mechanisms 
and physico-chemical factors responsible will have positive implications on drug 
development.58 
Additionally a cocrystal of Merck L-883555, a developmental phosphodiesterase-
IV inhibitor, and L-tartaric acid (0.5:1) showed more than 10 and 20-fold increase of 
Cmax and AUC, respectively, for 3mg/kg dose given orally in methocel to rhesus 
monkeys.59 Carbamazepine-saccharin (1:1) cocrystal has exhibited higher average 
cocrystal Cmax and AUC values relative to the marketed form III of carbamazepine in 
beagle dogs. Three different cocrystals of lamotrigine-nicotinamide were shown to have 
powder dissolution rates that were improved or equivalent to free lamotrigine at acidic 
and neutral pH conditions, respectively.  However, the two nicotinamide cocrystal forms 
administered to rats demonstrated lower serum concentrations.60 This discrepancy could 
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be caused by several factors such as the influence of the coformer on oral absorption or 
the oral suspension vehicle (PEG400 and methyl cellulose) that could change the 
thermodynamic stability or solubility of the cocrystal. Whatever the case, future animal 
experiments should carefully consider the thermodynamic solubility of cocrystals and the 




Caffeine converts to caffeine hydrate at high RH, which limits the processing and 
storage conditions of caffeine during development. However, the cocrystal of caffeine 
with oxalic acid was physically stable even at 98%RH up to 7 weeks. Moisture uptake 
studies done in our lab have also demonstrated the stability potential of the CBZ-NCT 




























100%RH, 22°C,  3 weeks
  98%RH, 22°C, 10 weeks
 
Figure 1.9: Moisture uptake of CBZ:NCT, CBZ:SAC, and single components.  Measured 
by thermal gravimetric analysis.61 
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Research Objective and Hypotheses: Key Questions 
 Can lower solubility cocrystals be synthesized by selecting coformers of lower 
solubility relative to a reference compound? How does the solid and solution phase 
mechanisms influence solubility behavior? 
 Can cocrystals provide solubility advantage over salts, and what are the key 
differences in the solubility-pH behavior of cocrystals and salts? 
 How can additives influence cocrystal synthesis? 
 Can cocrystal form in the solid state upon storage without cogrinding the reactants?  
Is there a thermodynamic driving force for spontaneous cocrystallization in the solid 
state? 
 What are the factors that influence the kinetics of cocrystal formation in the solid 
state during storage (temperature, relative humidity, disorder, material properties)? 
 
Statement of Dissertation Research 
 
The purpose of this dissertation is to investigate the solution phase chemistry and 
solids state properties of pharmaceutical cocrystals and analyze the thermodynamic basis 
for their solubility and stability. This research is focused on determining cocrystal 
properties in relation to the properties of their components, their environment such as 
solvent, pH, common ions, fusion properties, temperature and relative humidity. The goal 
is to gain insights with respect to cocrystal solid state and solution chemistry in order to 
improve the systematic approach for cocrystal design, synthesis, screening, selection and 
applications in drug delivery.  Phase behavior and solution equilibria are considered to 
provide general and accurate descriptions of the stoichiometric solubility of cocrystals 
that are either thermodynamically stable or unstable in pure solvent.  Cocrystal solubility 
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can be influenced by solid-state chemistry and solution chemistry including solute-
solvent interactions as well as ionization properties of its components and pH.  The 
influence of additives is also investigated, specifically the role of SLS is studied due to its 
ubiquitous presence in pharmaceutical formulations and testing media. The chapters 
presented describe important aspects of both solution and solid-state chemistry of 
cocrystals.   
 
Chapter 2 introduces four new cocrystals of a highly soluble compound 
gabapentin-lactam (GBPL). Crystallographic data is presented to resolve the crystal 
structure of these new cocrystals along with an in-depth analysis of solid state properties 
and solution phase chemistry to understand the aqueous solubility behavior. The 
thermodynamic basis for solubility and stability of GBPL cocrystals is discussed with the 
emphasis on how coformer solubility could influence cocrystal solubility. All GBPL 
cocrystals are less soluble than both the cocrystal components and their thermodynamic 
stability is highly dependent on pH. GBPL is non ionizable however, due to the ionic 
nature of coformers, cocrystal solubility is pH dependent.  All GBPL cocrystals exhibit 
pHmax where the cocrystal is in equilibrium with its component. Analogous to salts, 
detailed analysis of pHmax is presented with the generalized rules that will allow the 
estimation of pHmax for cocrystals as well as the parameters that will influence the 
magnitude of pHmax. The experimentally observed solubility of cocrystals is discussed 
and the differences in the experimental solubility from the calculated ideal solubility are 
explained on the basis of activity of the solute in solvent.  Our analyses show that there is 
a huge discrepancy between the observed and calculated solubilities of cocrystals 
resulting from the hydrophobicity of the solid leading to high values of activity 
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coefficient.  Melting point alone is therefore not the only criteria that govern the cocrystal 
solubility as two independent factors regulate cocrystal solubility. 
 
Chapter 3 presents the solubility pH dependence of several crystalline forms of a 
poorly soluble drug lamotrigine (LAM). Thermodynamic solubility of LAM salts and 
cocrystals is estimated.  For higher solubility cocrystals of LAM, solubility is estimated 
by measuring the eutectic concentrations of cocrystal components from which entire 
solubility pH profile is generated.  All cocrystals and salts exhibit a pHmax which dictates 
the thermodynamic stability of the solid phase in the solvent.  Key differences between 
the pHmax of cocrystals and salts are presented and generalized for applications to other 
such systems. We show how thermodynamic methods to determine solubility are more 
accurate than the reported kinetic methods, which can result in inaccurate values due to 
phase transformations. The effect of common ion is analyzed to determine the relative 
stability of LAM crystalline forms in the presence of Cl- and its influence on phase 
transformations. This is critical since Cl- is prevalent in physiological systems and 
physiologically relevant testing media.  Also in this chapter we examine the role of SLS 
on the synthesis, solubility and thermodynamic stability of lamotrigine nicotinamide 
cocrystal hydrate (LAM-NCT·H2O). The role of micellar solubilization on cocrystal 
solubility and stability is investigated.  Mathematical equations are developed based on 
cocrystal dissociation, component ionization, and micellar solubilization equilibria that 
describe cocrystal solubility as a function of thermodynamic parameters (Ksp, Ka, and 
micellar solubilization constant Ks). 
Chapter 4 investigates the mechanisms of cocrystal formation in the solid state. 
This chapter describes how cocrystals can form with no external energy applied such as 
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by applying mechanical stress as in milling, heating of the reactants, moisture induced 
etc, but simply from physical mixture of cocrystal components. The goal is to examine 
the factors that influence the kinetics of transformation of cocrysals from solid reactants.  
These factors include the effect of storage temperature and relative humidity, effect of 
milled vs. unmilled reactants and effect of annealing.  It is observed that high temperature 
and relative humidity as well as milling of reactants prior to mixing enhance the rate of 
cocrystal formation. 
Chapter 5 examines the solid state thermodynamic properties that impact the solid 
to solid conversion of reactants to cocrystals. Models have been shown previously for 
racemic compounds, however unlike racemic compounds, the components of cocrystals 
differ in their molecular structure, temperature and heat of fusion. Thermodynamic cycles 
were generated to develop mathematical equations for calculating free energy of 
cocrystal formation from its reactants. This type of investigation is developed for the first 
time for cocrystals. Reactant properties such as temperature and heat of fusion, heat 
capacity, entropy and enthalpy of mixing were used to derive these models to predict the 
cocrystal formation from reactants. Rigorous mathematical treatment is developed which 
is presented in a simplified manner for application along with general guidelines.  
Thermal behavior of carbamazepine-nicotinamide (CBZ-NCT) cocrystal has been studied 
by calorimetry. Thermal events are characterized, which are useful in understanding 
several features of cocrystals such as, interaction with reactants, eutectic melt behavior, 
purity as well as nature of the impurity. This data is used to generate a binary phase 
diagram which is very useful in understanding the general behavior of cocrystals as a 
function of temperature and composition. 
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Finally, the conclusions and future work of this dissertation research are provided 
in Chapter 6. Future challenges include, how surfactants can influence cocrystal 
formation and the mechanism of reaction involved at the molecular level resulting in 
cocrystal formation in the presence of surfactants.  How the non-ideality influences the 
free energy of cocrystal formation in physical mixtures of its reactants? The role of 
reactants can influence mixing enthalpies thereby influencing the magnitude as well as 
the sign of free energy of formation of cocrystals in the solid state from its reactants. This 
will lead to generalized applications of these concepts and greater predictive power from 
simple thermodynamic calculations.  Each chapter begins with its abstract and ends with 
a conclusion. 
Several of these chapters have been published. Tailoring aqueous solubility of 
GBPL via cocrystallization and the effect of coformer ionization, pHmax and solute-
solvent interactions described in Chapters 2 is published in CrystEngComm Vol. 14, pp. 
4801-4811, 2012.  
Factors that influence spontaneous formation of pharmaceutical cocrystals by 
simply mixing solid reactants described in chapter 4 is published in CrystEngComm, 
Vol .11, pp. 493-500, 2009.  
Chapter 3 discussing the cocrystal solubility advantages over salts and the 
importance of thermodynamic solubility measurements to assess true solubility as well as 
the role of surfactants in cocrystal synthesis is in draft for submission at the time of 
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TAILORING AQUEOUS SOLUBILITY OF A HIGHLY SOLUBLE COMPOUND 
via COCRYSTALLIZATION: EFFECT OF COFORMER IONIZATION, pHMAX 
AND SOLUTE-SOLVENT INTERACTIONS 
 
Abstract 
Cocrystals of a nonionizable, water soluble compound (gabapentin-lactam (GBPL)) with 
less soluble coformers, are shown to be 2 to 17 times less soluble than GBPL.  Cocrystals 
of GBPL with gentisic acid, 4-hydroxybenzoic acid, 4-aminobenzoic acid and fumaric 
acid are characterized by carboxylic acid---amide hydrogen bonds between coformer and 
GBPL, consistent with a previously reported structure of a benzoic acid cocrystal.  The 
lattice and solvation contributions to cocrystal aqueous solubility were evaluated and 
solvation was found to be the main contribution to solubilization.  Cocrystals exhibited 
pH-dependent solubility and pHmax, both of which are described by coformer pKa and 
cocrystal Ksp values.  These findings have important implications for the characterization 






In the development of a dosage form, aqueous solubility is one of the principal 
attributes that must be considered in order to develop a safe, efficacious and consistent 
product.  Some of the commonly used approaches for solubility modification are the use 
of amorphous materials, solid dispersions, prodrugs, molecular salts and cocrystals.1-5  
Cocrystals provide an alternative to salt formation for non-ionizable compounds and can 
impart pH dependent solubility behavior with the use of an ionizable coformer.  Cocrystal 
aqueous solubility and its dependence on pH can be engineered by the choice of 
coformers and their ionization properties.3, 6 From a solubility perspective, cocrystal 
research has mainly focused on enhancing drug solubility for achieving increased 
dissolution rate, thereby improving bioavailability. Depending on the desired 
pharmacokinetic effect, alternative solid forms such as salts, cocrystals and prodrugs can 
also be used to prolong the release of active compounds.  Controlling release kinetics is 
of importance in the case of drugs exhibiting short half lives, large Cmax values or toxicity 
due to high solubility. 
2, 7-9 
Methods to alter the solubility are based on the free energy of solubilization, 
which involves crystal lattice interactions as well as interactions between solute and the 
solvent (solvation).1, 10-12  Strategies that can modulate solute-solvent interactions to alter 
solubility include ionization, complexation, micellar solubilization, prodrugs and 
cosolvents.  These two factors contribute to the associated overall free energy of solution 
of a compound, which is given by, 
Gsolution  Glattice  Gsolvation  
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where ΔG represents the Gibbs energies associated with the solubilization process, lattice 
and solvation.  Several approaches can be utilized to alter the lattice energy of the solute, 
for example, formation of amorphous phases, polymorphs, solvates, salts and cocrystals.  
Solvation plays a critical role on solubility, especially for hydrophobic drugs.10, 13  
Cocrystals have the ability to modulate both solid and solution phase chemistry and 
consequently influence the associated lattice and solvation energies.   
Enhancing the aqueous solubility of water insoluble drugs is well documented, 4, 14-19 
the ability to decrease aqueous solubility is less recognized.3, 8, 20   The purpose of the 
work presented here was to determine (i) the influence of low solubility coformers on 
cocrystals of a high solubility compound, (ii) the influence of crystal lattice energy on 
cocrystal aqueous solubility, (iii) the relationship between coformer ionization properties 
and cocrystal solubility-pH dependence, and (iv) the dependence of cocrystal 
thermodynamic stability on pH. 
Cocrystal thermodynamic solubility has been correlated to the coformer solubility 
when solvation is the main barrier to solubilization.  Cocrystals composed of coformers 
with a solubility of at least 10-fold higher than the drug have been observed to enhance 
cocrystal solubility.4, 20  Cocrystallizing a highly soluble drug with a coformer exhibiting 
lower solubility will likely produce a cocrystal with a lower solubility than its drug 
component.  For example, cocrystallizing the highly soluble gabapentin (GPB) with the 
less soluble 3-hydroxybenzoic acid (3HBA) results in a cocrystal which is 0.2 times the 
solubility  of GBP (5 times less soluble).3   3HBA has an aqueous solubility of 0.06 (M) 
at pH 2.8 (pKa – 4.06 and 9.92), which is 0.07 times the solubility of GBP (0.88 M) at pH 
7.3 (pKa – 3.68 and 10.70) at room temperature.
3   
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The cyclization of the charged aminocarboxylic acid moiety of GBP results in a five 
membered uncharged cyclic lactam in gabapentin-lactam (GBPL) with secondary amine 
and carbonyl groups (Scheme 2.1). Gabapentin-Lactam (GBPL) is a non-ionizable 
compound with high aqueous solubility and potential pharmacologic activity.21, 22   
Scheme 2.1: Chemical structures of GBP and GBPL 
  
Due to its high aqueous solubility and non-ionizable nature in physiological pH range, 
GBPL was chosen as the model compound for investigation.  Carboxylic acids were 
selected as coformers based on their low aqueous solubility relative to GBPL, ionizable 
characteristics, and their ability to form strong acid ··· amide heterosynthons.  The 
reported aqueous solubilities of the selected coformers range from 0.14 to 0.75 relative to 
GBPL solubility and have pKa values that range from 2.4 to 4.8.
23-30   
 A search of the Cambridge Structural Database (CSD) showed that molecules 
containing carboxamide moieties form multicomponent crystal forms with carboxylic 
acids via synthon. Zaworotko and coworkers published a CSD survey of 
compounds containing primary amides and carboxylic acid groups that suggested that 
47% of the structures formed acid ··· amide heterosynthons while 44% and 6% structures 
formed amide ··· amide and acid ··· acid homosythons respectively.
2
2R (8)
31 The strength of acid 
··· amide heterosynthon was exploited in the discovery of GBPL cocrystals with gentisic 
acid (GA), 4-hydroxybenzoic acid (4HBA), 4-aminobenzoic acid (4ABA) and fumaric 
acid (FA). The solubility behavior of a previously discovered cocrystal of GBPL with 
 41
benzoic acid (BA)32 is also investigated in this manuscript. The molecular structures of 
compounds used are shown below. 
   
   
            Scheme 2.2: Compounds Used in Cocrystallization 
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Materials and Methods 
 
Materials 
GBPL (97+% purity) was purchased from Waterstone-Technology, LLC., Carmel IN.  
Gentisic acid (GA), benzoic acid (BA), 4-hydroxybenzoic acid (4-HBA), 4-aminobenzoic 
acid (4ABA) and fumaric acid (FA) were obtained from Sigma-Aldrich and were of 99+ 
% purity.  All materials were used as received.  X-Ray powder diffraction (XRPD) and 
differential scanning calorimetry (DSC) were used to characterize the materials prior to 
use.  
 
Cocrystal Synthesis   
Cocrystals were synthesized from near saturated aqueous solutions of the higher 
solubility component, which is GBPL in these studies, according to the reaction 
crystallization method (RCM).20, 33 An equimolar mass of coformer was added to the 
solution of GBPL in water at room temperature and stirred for 12 hours.  The solid form 
recovered was analyzed by XRPD and DSC, and purity was confirmed by HPLC and 
DSC prior to single crystal determination. 
 
X-ray Powder Diffraction (XRPD) 
XRPD patterns of solid phases were recorded with a Rigaku MiniFlex X-ray 
diffractometer (Danvers, MA) using Cu Ka radiation (λ = 1.5418 Å), a tube voltage of 30 
kV, and a tube current of 15 mA. The intensities were measured at 2θ values from 2° to 
40° with a continuous scan rate of 2.5°/min.  The X-ray powder diffraction patterns of 
new cocrystals of GBPL are provided in the supporting information. 
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Single-crystal X-ray Diffraction (SCXRD) 
SCXRD data of new phases of GBPL-4HBA, GBPL-4ABA and GBPL-FA were 
determined at 293 and 150K on a Bruker AXS-KAPPA APEX II diffractometer with 
graphite-monochromated radiation (Mo K, =0.71069 Å).  Data for GBPL-GA was 
collected on a Bruker SMART APEX CCD-based X-ray diffractometer (Mo K, 
=0.71069 Å) at 85K.  All the data were corrected for Lorentzian, polarization and 
absorption effects using SAINT and SADABS programs.  SIR97 34 was used for structure 
solution and SHELXL-97 35 was used for full matrix least-squares refinement on F2.  All 
non-hydrogen atoms were refined anisotropically, except in GBPL2-FA where a 
disordered model on the carboxamide moiety of GBPL enforced an isotropic refinement 
of the C and N atoms.  A disorder model was also applied to the cyclohexane ring in 
GBPL-4HBA.  Both carboxylic groups of 4HBA and FA show some disorder with the H 
atom sharing two positions with split occupancy of 65:35%.  HNH atoms were located 
from a difference Fourier map and their positional coordinates and isotropic parameters 
were refined, except in the disordered GBPL2-FA carboxamide moiety.  HCH atoms were 
added in calculated positions and refined isotropically riding on their C atoms.  
MERCURY 2.3 was used for molecular representations and packing diagrams.  Single 
crystal data were used to simulate theoretical XRPD patterns that were compared with 
experimental data to ascertain the purity of the samples. 
 
Thermal Analysis 
Crystalline samples of 2-4 mg were analyzed by DSC using a TA instrument (Newark, 
DE) 2910 MDSC system equipped with a refrigerated cooling unit.  DSC experiments 
were performed by heating the samples at a rate of 10 K/min under a dry nitrogen 
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atmosphere. High purity indium standard was used for temperature and enthalpy 
calibration of the instrument. Standard aluminum sample pans were used for all 
measurements. Cocrystal samples for DSC analysis comprised several large crystals 
grown by slow partial evaporation of solutions containing the reactants. These crystals 
were isolated from solution, washed, and characterized by X-Ray diffraction before DSC 
analysis.  The mean result of a minimum of three samples is reported for each substance.  
Purity analysis of the cocrystal powder was analyzed and confirmed by the presence of a 
single endothermic event. 
 
Solubility Measurement 
All solubility measurements were carried out in aqueous medium at 25 ± 0.1ºC.  pH was 
adjusted by adding 0.1N HCl or 0.1N NaOH.  Solution concentrations of both cocrystal 
components were measured by HPLC. Solutions were considered to have reached 
equilibrium when less than 5% change in concentration was detected in either component 
of the cocrystal when measured subsequently over a period of 48-72 hours. Solubility 
product (Ksp) was calculated from measured concentration of cocrystal components at 
different pH values. Solid phases were characterized by XRPD and DSC at the end of the 
solubility experiments.   
 
Nuclear Magnetic Resonance (NMR) 
 
Chemical stability of GBPL in coformer aqueous solutions was confirmed by solution 
NMR. Solution NMR was also used to confirm the absence of interaction between GBPL 
and coformers in the solution phase.  Proton decoupled 13C NMR spectra were recorded 
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on a Bruker DRX500 spectrometer (11.75T) at a probe temperature of 298K, tuned to 
125.7 MHz, using 5mm high resolution NMR tubes.   
 
High-Performance Liquid Chromatography (HPLC)  
Purity and stoichiometry of the GBPL cocrystals was analyzed by HPLC before carrying 
out pH dependent solubility studies.  Solution concentrations of drug and coformer were 
analyzed by Waters HPLC (Milford, MA) equipped with a UV/vis spectrometer detector. 
A C18 Atlantis column (5 μm, 4.6 × 250 mm; Waters, Milford, MA) at ambient 
temperature was used to separate the drug and the coformer.  An isocratic method with a 
mobile phase composed of 45% water, 55% methanol and 0.1% trifluoroacetic acid was 
used with a flow rate of 1 mL/min.  Sample injection volume was 20 μL.  Absorbance of 
the drug and coformer analytes was monitored between 210-300nm.  Empower software 
from Waters Inc., was used to analyze the data.  All concentrations, unless otherwise 
indicated are reported in molality (moles solute/kilogram solvent). 
 
 46
Results and Discussion 
Four cocrystals of GBPL with GA, 4HBA, 4ABA and FA were discovered by reaction 
crystallization method (RCM). The hydrogen bonding patterns of these cocrystals as well 
as the previously discovered GBPL cocrystal with BA are presented in Figure 2.1.  
Crystallographic and structural data of GBPL cocrystals are listed in Table 2.1. 
 
      
Figure 2.1: Hydrogen-bond patterns of GBPL cocrystals; (a) GBPL-BA (b) GBPL-GA 
(c) GBPL-4HBA (d) GBPL-4ABA and (e) GBPL2-FA. 
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Table 2.1: Crystallographic data and structure refinement parameters of GBPL cocrystals 
 
 
GBPL-GA GBPL-4HBA GBPL-4ABA GBPL2- FA 
Chemical formula C16 H21 N O5 C16 H21 N O4 C16 H22 N2 O3 C11 H18 N O3 
Mr 307.34 291.34 290.36 212.26 
Temperature/K 85 150 150 150 
Wavelength / (Å) 0.71073 0.71069 0.71069 0.71069 
Morpholgy, colour Needle, colorless Thin plate, colorless Parallelepiped, colorless Needle, colorless 
Crystal size/mm 0.40 x 0.19 x 0.04 0.08 x 0.04 x 0.02 0.22 x 0.05 x 0.04 0.20 x 0.03 x 0.02 
Crystal system Monoclinic Triclinic Monoclinic Monoclinic 
Space group P21/n P1 P21/n P21/c 
a/Å 5.9663(6) 6.3900(4) 5.9280(6) 10.7040(3) 
b/Å 27.045(3) 10.0780(7) 18.465(2) 6.0110(4) 
c/Å 9.470(1) 12.2260(8) 14.208(1) 17.802(6) 
/° 90 81.714(3) 90 90 
/° 107.008(2) 82.039(3) 99.259(5) 101.372(3) 
/° 90 76.597(3) 90 90 
V/Å3 1461.3(3) 753.37(9) 1535.0(3) 1122.9(4) 
Z 4 2 4 4 
/mg.m-3 1.397 1.284 1.256 1.256 
/mm-1 0.104 0.092 0.087 0.091 
Reflections collected/unique 32048/3647 8801 / 3034 10262/2922 7576 / 2097 
R int 0.0501 0.0277 0.0392 0.0466 
Goodness of Fit 1.099 1.055 1.131 1.11 
Final R indices [I>2(I)] 
R1 = 0.0445 
wR2 = 0.1067 
R1 = 0.0482 
wR2 = 0.1300 
R1 = 0.0446 
wR2 = 0.1539 
R1 = 0.0600 
wR2 = 0.2063 
        
GBPL-GA cocrystal 
GBPL-GA crystallizes in the P21/n monoclinic space group, with one molecule of each 
component per asymmetric unit. Although the usual S(6) intramolecular O-H···O 
hydrogen bond between the hydroxyl and carbonyl moieties is maintained within gentisic 
acid molecules, the homomeric synthon previously mentioned for gabapentin-
lactam is disrupted and replaced by a heteromeric synthon responsible for the 






GBPL···OGA and O-HGA···OGBPL interactions.  Two pairs of dimers are connected via O-
HGA···OGBPL interactions between the hydroxyl donor moiety of the coformer and the 
carboxamide moiety of GBPL, giving rise to tetramers.  These tetramers are different 
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from the ones based in the homosynthon as there are no external functional groups in the 




GBPL-4HBA crystallizes in the P−1 triclinic space group, with one molecule of each 
compound per asymmetric unit.  The C-O distances in the carboxylic moiety of the 
coformer are similar and the electron density map indicates disorder with the H atom 
sharing two positions with refined split occupancy of 65:35%.  The carboxamide moiety 
interacts with hydroxyl of 4HBA via O-H4HBA···OGBPL to form a tetrameric motif.  This 




4HBA···O4HBA, between two coformer molecules, giving rise to chains of alternated 
GBPL and coformer dimers making a 35º angle.  No supramolecular interactions are seen 
between consecutive chains. 
 
GBPL-4ABA cocrystal  
4ABA is an amphoteric coformer.  GBPL-4ABA crystallizes in the P21/n monoclinic 
space group, with one molecule of each component per asymmetric unit.  GBPL crystal 
packing is based on N-H···O interactions inducing the formation of dimers through the 
homomeric synthons between the carboxamide moieties.  This motif is also the 
basis for GBPL-4ABA supramolecular arrangement.  In this new cocrystalline form the 




4ABA···OGBPL bonds to form the tetrameric motif, exploiting the double acceptor ability 
of the carbonyl oxygen, reinforced by N-HGBPL···O4ABA interaction.  The N-
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H4ABA···O4ABA and N-H4ABA···OGBPL interactions are responsible for the linkage of these 
tetramers to other similar patterns along a and b axes.  The extended supramolecular 
packing of this cocrystal is characterized by alternated zig-zag chains of coformer and 
GBPL interacting through N-HGBPL···O4ABA, O-H4ABA···OGBPL and N-H4ABA···OGBPL. 
 
GBPL2-FA cocrystal  
FA is a diprotic acidic coformer.  GBPL2-FA crystallizes in the monoclinic P21/c space 
group.  It’s asymmetric unit consists of one GBPL molecule and the fumaric acid resides 
on an inversion centre.  The typical homosynthon forming dimers of GBPL is 
observed.  In this case, the amide moiety of GBPL works as a double donor, further 
interacting with the coformer via N-H
2
2R (8)
GBPL···OFA forming tetramers, reinforced by O-
HFA···OGBPL.  Tetramers are linked due to the special position of FA.  GBPL dimers are 
intercalated by coformer, forming a chain.  
The previously reported GBPL-BA cocrystal,32 presents both resemblances and 
dissimilarities with the ones discussed herein.  In the GBPL-BA cocrystal the GBPL 




BA···OGBPL interactions and similarly to what is seen in the GBPL-GA 
cocrystal, the tetrameric motifs are not hydrogen-bonded between them.  Tetramers are 
extended to form alternated zig-zag chains of GBPL and BA.  The cocrystal of GBP with 
3HBA also exhibits a tetramer such that both carboxylic and phenolic OH donors form 
O-H···O- interactions with GBP.  However, unlike the GBPL-GA tetrameric motifs 
which are not hydrogen bonded, the GBP-3HBA tetrameric motifs are connected by 
charge assisted N+- H···O- hydrogen bonds forming a layered structure.3 
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Influence of Lattice and Solvation Energies on GBPL Cocrystal Solubility 
The solubilization of a cocrystal involves two separate processes, (i) release of 
solute molecules from the crystal lattice and (ii) solvation of the released solute 
molecules.  Each of these factors contributes to the free energy of solubilization and 
therefore to the observed solubility value.  The lattice energy contribution is calculated 

















   (2.1) 
where cideal is the ideal mole fraction solubility of a solute at a temperature (T), Tf is the 
fusion temperature, and  ∆Hf  is enthalpy of fusion.  This equation assumes that the heat 
capacity change upon melting is negligible. 
Table 2.2 summarizes the ideal solubility values and measured aqueous 
solubilities of cocrystals and single components.  Ideal solubility values were calculated 
according to equation (2.1) from measured fusion parameters. Table 2.2 shows that the 
melting points (MP) of GBPL cocrystals are in between that of its components, with the 
exception of GBPL-BA cocrystal, which has a MP lower than its components.  The ideal 
solubilities range from 0.36 to 1.74 times that of GBPL ideal solubility, while the 
experimental solubilities range from 0.06 to 0.52 times GBPL solubility.  This indicates 
that while cocrystals can increase solubility via changes in lattice energies, ultimately the 
lower coformer solubility relative to the drug results in observed lower cocrystal 
solubility.  
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observed and ideal solubility valu
aq ideal aqlog log log
where χaq is the observed solubility and γaq is the activity coefficient, which represents 
the contribution of solute-solvent interactions.11, 13  Equations (2.1) and (2.2), were used 
to calculate the ideal solubilities and activity coefficients for GBPL cocrystals (Figure 
2.2).  A similar analysis has been presented to study the role of solvent and molecular 





Figure 2.2 shows the experimental aqueous solubility values for all cocrystals are 
er than the calculated ideal solubility values.  Solvation in this series of cocrystals 
e a significant barrier to the experimental aqueous solubility, which is lower 
al solubility by as much as 3 orders of magnitude.  This difference between 
es is quantitatively expressed by 
         (2.2) 
 
     
Figure 2.2: The lattice energy (log χideal) and solvation energy (log γaq) contributions to 
the experimental aqueous solubility of GBPL and GBPL cocrystals is arranged in order 
of increasing ideal solubility (Sideal).  The black area of the bars represents Sideal 
calculated from equation (2.1).  The grey area represents the activity coefficient 
calculated from equation (2.2).  
 
With respect to the series of GBPL cocrystals examined, lower solubility 
coformers led to cocrystals of lower solubility relative to GBPL, however the magnitude 
of solute-solvent interactions (γaq) is not proportional to the magnitude of their calculated 
ideal solubilities (χideal). As a result melting point is not an accurate measure in predicting 
aqueous solubility of GBPL cocrystals.  Similar solubility trends have been observed for 
other cocrystals,4, 37 suggesting that it is often difficult to predict the solubility of a 
cocrystal in water based on its thermal properties alone, since solvation can be the factor 





Influence of Coformer Ionization on Cocrystal Solubility 
GBPL forms cocrystals of 1:1 stoichiometry with monoprotic acidic coformers (GA, BA 
and 4HBA), 2:1 cocrystal with diprotic acidic coformer (FA) and a 1:1 cocrystal with 
amphoteric coformer (4ABA). The solubility dependence on coformer ionization for a 
1:1 cocrystal of a non-ionic compound and a monoprotic acidic coformer can be 














     (2.3) 
where Ksp is the solubility product of the cocrystal,  is the ionization constant of the 
acidic coformer, and [H
a,HAK
+] is the hydrogen ion concentration. The cocrystal Ksp can be 
calculated from the measured total drug [GBPL]T and the total coformer [HA]T solution 













T     (2.4) 
 The solubility-pH dependence of GBPL-GA, GBPL-BA and GBPL-4HBA 
cocrystals, coformers and GBPL are shown in Figure 2.3. Cocrystal solubility curves 
were generated from equation (2.3) with cocrystal Ksp values given in Table 2.3. Ksp 
values were evaluated from the linearized form of equation (2.4) from measured cocrystal 
solubilities at several pH values. The solubility of GBPL at 25ºC in pH 1, 3 and 5 was 
measured to be 0.180 ± 0.004m.  Figure 2.3 indicates that cocrystal intrinsic solubilities 
are lower than GBPL and coformer solubilities, and range from 0.06 to 0.10 times the 
GBPL solubility.  Intrinsic solubility is the solubility under non-ionizing conditions of 




are in excellent agreement with the predicted behavior. There is an intersection between 
the cocrystal and the GBPL solubility curves at a given pH value, pHmax.  At pHmax the 
solution is saturated with both GBPL crystal and cocrystal.  Below pHmax cocrystal is 
thermodynamically stable.   The value of pHmax for these cocrystals range from 5.3 to 6.6.  






Figure 2.3: Experimental and predicted solubility-pH dependence of cocrystals expressed 
in terms of GBPL molal concentrations.  Cocrystal and GBPL solubilities are represented 
by (●) and (○) respectively. Theoretical solubility (──) dependence on pH for (a) GBPL-
GA (b) GBPL-BA and (c) GBPL-4HBA calculated from equation (2.3) using Ksp values 
of 1.32 x 10-4, 3.43 x 10-4 and 2.16 x 10-4 m2 and pKa values in Table 2.3. Theoretical 
coformer solubility-pH dependence (·····) was generated from equation (2.5) using pKa 
















  (2.5) 
From measured coformer solubility at a given pH, and reported pKa values of GA, BA 
and 4HBA intrinsic solubilities  0,coformerS  were calculated (Table 2.2 and Table 2.3).  
Coformer intrinsic solubilities range from 0.14 to 0.75 times the solubility of GBPL and 
are in good agreement with solubilities reported in the literature.23-30 
GBPL2-FA cocrystal exhibits 2:1 stoichiometry. The cocrystal solubility 
dependence on coformer ionization is described by:  
22










    (2.6) 






sp can be calculated from the total drug [GBPL]T and the total coformer 















































   (2.7) 
The predicted cocrystal and coformer (FA) solubility pH dependence was calculated from 




solubility (Table 2.2 and Table 2.3). Results in Figure 2.4 show that the intrinsic 
solubility of GBPL2-FA cocrystal is 0.52 times the GBPL solubility. The predicted 
increase in solubility with pH is in excellent agreement with experimental behavior and 
shows a pHmax of 3.7.  At the pHmax, the equilibrium solubility of crystalline GBPL is 
equal to the GBPL2-FA cocrystal solubility expressed in terms of GBPL moles.   
     
Figure 2.4: Experimental and predicted solubility-pH dependence of GBPL2-FA 
cocrystal at 25ºC expressed in terms of GBPL molal concentration.  Cocrystal and GBPL 
solubility are represented by (●) and (○) respectively. Theoretical solubility-pH 
dependence (──) was calculated from equation (2.6) using Ksp value of 4.13 x 10
-4m3 
and the pKas listed in Table 2.3.  Theoretical FA solubility-pH dependence (·····) was 
calculated from equation (6) using the pKas in Table 2.2 and the measured FA solubility 







GBPL forms a 1:1 cocrystal with amphoteric coformer 4ABA.  The cocrystal 















    (2.8) 
a,HAX




sp can be calculated from the total drug [GBPL]T and the total coformer 























    (2.9) 
Figure 2.5 shows excellent agreement between the predicted and observed GBPL-4ABA 
cocrystal solubilities.  Due to the amphoteric nature of 4ABA, a ‘U’ shaped solubility-pH 
profile of GBPL-4ABA cocrystal is obtained and there are two pHmax values given by the 
intersection points of the GBPL and cocrystal solubility curves.  GBPL-4ABA cocrystal 
is the stable solid phase in the region between the two pHmax values of 0.8 and 6.6. 
GBPL-4ABA cocrystal exhibits a lower solubility relative to both GBPL and 4ABA.  







Figure 2.5: Experimental and predicted solubility-pH dependence of GBPL-4ABA 
cocrystal at 25ºC expressed in terms of as GBPL molal concentrations. Cocrystal and 
GBPL solubilities are represented by (●) and (○) respectively. Theoretical solubility 
dependence on pH (──) was calculated from equation (2.8) using Ksp value of 8.41 x 10
-
4 m2 and the pKa values in Table 2.3. 4ABA solubility-pH dependence (·····) was 
calculated from equation (2.10), values in Error! Reference source not found. and a 
measured 4ABA solubility shown by (□). 
 


















    (2.10) 
using the measured 4ABA solubility at a given pH and reported Ka values (Table 2.2 and 
Table 2.3). Cocrystal Ksp was evaluated from the slope of the linearized form of the 
solubility equations (2.3), (2.6) and (2.8), are shown in Figure 2.6.  Ksp values are 







Figure 2.6: Plots used to evaluate cocrystal Ksp for (a) GBPL-GA (b) GBPL-BA (c) 
GBPL-4HBA according to equation (2.3) (d) GBPL2-FUM according to equation (2.6) 




The solubility-pH dependence of an ionizable compound and its salt has been previously 
described by two independent curves, one where the free base (or acid) is the saturation 
species and the other where the salt is the equilibrium species and the point where the two 
saturation curves intersect is the pHmax. 
1, 2, 12, 38, 39  pHmax has been referred to as , 
since the presence of two solid phases imparts the Gibbs phase rule constraint by forcing 




12, 38  The solubility-pH dependence of 
GBPL cocrystals is summarized in Figure 2.7, and the mathematical basis to predict the 
pHmax dependence on Ksp, cocrystal component solubility and ionization behavior is 





Figure 2.7: Cocrystal solubility expressed as GBPL molal concentration plotted as a 
function of pH. Curves were generated using models that describe cocrystal solubility-pH 
dependence using parameter values from Table 2.2 and Table 2.3.  At pHmax, GBPL and 
cocrystal is in equilibrium with a solution saturated with respect to both cocrystal and 
GBPL.  
 
The pHmax of a 1:1 cocrystal occurs where Scc = SGBPL. For the 1:1 GBPL 
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      
For the 1:1 GBPL cocrystal with an amphoteric coformer the pHmax is obtained from 
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       (2.12) 
Equation (2.12) is the solution of a quadratic expression and thus results in two pHmax 
values.  
 The 2:1 cocrystal of a non-ionic compound with diprotic acidic coformer such as 
GBPL2-FA cocrystal exhibits a pHmax when 2Scc=SGBPL which can be expressed as 
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      (2.13) 
Equation (2.13) is obtained by setting GBPL solubility equal to the solubility of the 2:1 
cocrystal of GBPL2-FA (in terms of GBPL moles), and solving for [H
+]. This is the 




The pHmax for GBPL cocrystals (Table 2.3) were measured and calculated from 
cocrystal Ksp, coformer pKa and GBPL solubility. The calculated pHmax values were 
confirmed experimentally for GBPL-4HBA and GBPL-4ABA cocrystals.  In the case of 
GBPL-GA, GBPL-BA and GBPL2-FA cocrystals, pHmax could not be accessed 
experimentally.  This is due to self-buffering of the coformer which would not allow for 
independent pH adjustment. 
  
Table 2.3: Ksp and pHmax values of GBPL cocrystals at 25ºC 
 (a) The unit of Ksp for 1:1 cocrystals is m
2 and for GBPL2-FA cocrystal is m
3. (b), (c) and (d) represent 
Ksp values calculated from equations (2.3), (2.6) and (2.8) respectively using measured aqueous solubility 
values as a function of pH. Plots used to calculate Ksp are shown in Figure 2.6. (e), (f) and (g) represent 
pHmax calculated from equations,(2.11), (2.12) and (2.13) respectively. 
Cocrystal 
Ksp ± Std. Error 
m2 or m3 a 
Coformer pKa pHmax 
GBPL-4HBA (2.16 ± 0.06)x10-4 b 4.4 
40, 41 6.6 e 
GBPL-4ABA (8.41 ± 0.05)x10-4 c 
2.4 (amine) 
4.8 (acid) 42 
0.8 f 
6.4 f 
GBPL-BA (3.4 ± 0.1)x10-4 b 4.2 
43 6.2 e 
GBPL-GA (1.32 ±0.03)x10-4 b 2.9 
44-46 5.3 e 
GBPL2-FA (4.1± 0.3)x10-4 d 3.0 and 4.4 
47 3.7 g 
 
pHmax for GBPL cocrystals with acidic coformers ranges from 3.7 to 6.6.  Both Ksp 
and pKa influence the value of pHmax.  Larger Ksp and smaller pKa values result in a 
lower pHmax.  The lowest cocrystal pHmax values are shown to be associated with low 
coformer pKa and high solubility (in terms of GBPL) as seen for the GBPL2-FA (Scc= 
9.38x10-2 m). GBPL-GA (Scc= 1.15x10
-2 m) with similar pKa and lowest cocrystal 
solubility in this series of cocrystal exhibits the next lowest pHmax.  
General relationships between cocrystal Ksp and coformer pKa on cocrystal pHmax for 
a 1:1 cocrystal of a non-ionizable drug and an acidic coformer, can be predicted by 




1. An order of magnitude increase in Ksp, decreases pHmax by 1 unit. 
2. A unit increase in coformer pKa value, increases pHmax by 1 unit. 
3. An order of magnitude increase in drug to cocrystal solubility ratio (SDrug/SCocrystal), 
increases pHmax by 2 units.  
The general sensitivity of cocrystal pHmax on these parameters is graphically 




      
Figure 2.8: (a) increase in Ksp by an order of magnitude decreases the pHmax by 1 unit, 
(b) increase in pKa by 1 unit increases the pHmax by 1 unit and (c) increase in the drug to 




pHmax expressions are useful in calculating cocrystal stability regions.  
Understanding cocrystal thermodynamic stability as a function of pH is useful for 
designing synthesis methods and understanding the in-vitro and in-vivo solubility related 
performance where pH is often a critical variable and may have a role in reversible 
transformations between cocrystal and drug.   
 
Conclusions 
 Reaction crystallization method was successfully utilized to discover four 
cocrystals of GBPL. Cocrystallizing the highly soluble GBPL with lower solubility 
coformers results in cocrystals with a lower solubility than GBPL as hypothesized.  
Solvation was shown to be a key factor in determining cocrystal solubility. For the first 
time, mathematical models describing cocrystal pHmax are described. Mathematical 
models based on ionization properties and cocrystal Ksp accurately predict cocrystal 
solubility-pH dependence and pHmax.  pHmax is of importance in estimating cocrystal 
solubility behavior and stability in aqueous solutions, which is critical for cocrystal 
synthesis and in-vitro, in-vivo performance.  Thus the ability of cocrystals in providing 
varying solubility and solution concentrations to a non-ionizable compound over a wide 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A1.3: Figure plotted from the data in Table A1.2 showing the trend between 
ratio of coformer and cocrystal melting point to the melting point of the compound wh
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           CHAPTER 3 
 





The purpose of this work was to determine the extent to which aqueous solubility, 
pHmax, and thermodynamic stability can be altered by cocrystals and salts of a basic drug. 
Lamotrigine (LAM) cocrystal with nicotinamide (NCT) and LAM salt with saccharin 
(SAC) were used as model compounds, while the reported data for lamotrigine-
methylparaben (LAM-MP) and LAM·HCl were used to draw pH dependent solubility 
comparisons of LAM solid forms. Reaction crystallization was used to synthesize LAM-
NCT·H2O cocrystal hydrate and LAM-SAC salt.  Supersaturation was controlled by use 
of sodium lauryl sulfate to obtain highly pure LAM-NCT·H2O cocrystal. Mathematical 
models developed by considering solid-solution equilibria were used to generate the 
predicted pH dependent solubility of cocrystal and salt. These models were challenged by 
measuring pH dependent solubility and eutectic point concentration of cocrystal 
components which represents the cocrystal solubility under non stoichiometric conditions 
where solid drug and cocrystal are in equilibrium with the solution. LAM-NCT·H2O 
cocrystal and LAM-SAC salt are 30 and 5 times more soluble than LAM·H2O 
respectively, while LAM-NCT·H2O cocrystal is 6 times more soluble than LAM-SAC 
salt.  This solubility comparison is based on the pH values at which the crystalline forms
 
are in their intrinsic solubility state. A pHRmaxR value of 2.7 exists between LAM-NCT·HR2RO 




phase relative to LAM·H2O, while a pHmax value of 5.0 exists between LAM-SAC salt 
and LAM·H
R R R R
2O below which LAM-SAC salt is the stable solid phase. pHmax is a critical 
thermodynamic parameter which governs cocrystal and salt stability and can be 
accurately calculated from the equations based on solid solution equilibria.  The predicted 
solubility behavior calculated from the mathematical models is in excellent agreement 
with experimental results. The thermodynamic solubility rank order of LAM solid forms 
investigated in this work is, LAM-NCT·H2O > LAM-SAC > LAM-MP, and the coformer 
solubility rank order is NCT > SAC > MP.  Solubility of LAM·HCl salt is dependent on 
the Cl- concentration in the medium due to common ion effect. 
 
Introduction 
Approximately one-third of the new chemical entities have aqueous solubilities of 
less than 10µg/ml1.  Solubility often governs drug dissolution, and when bioavailability is 
limited by solubility, higher solubility forms may be useful to provide faster dissolution 
rates in the gastrointestinal tract resulting in improved bioavailability. The intended 
higher dissolution is often achieved via alternative solid forms such as salts, cocrystals 
and amorphous solids exhibiting higher solubility than the crystalline free drug. For 
several decades, pharmaceutical salts which are formed by charge assisted molecular 
bonds have been considered as the form of choice for poorly water soluble drugs2-6.  As a 
result a large number of drugs are marketed as salts7. Cocrystals offer a choice of solid 
forms for drug delivery when salt formation is not possible or when non-ionic hydrogen 
 
bonded interactions can be exploited to produce alternative crystalline forms of desirable 
properties, such as solubility modification.   
Lamotrigine [6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine] is a triazine drug 
that exhibits poor aqueous solubility and dissolution rate in its crystalline form.  It is used 
for the treatment of epilepsy and psychiatric conditions such as bipolar disorder.  LAM is 
a weakly basic compound with a pKa of 5.7
8 and reported aqueous solubility of 
0.17mg/ml9-12.  Enhancing solubility of such poorly water soluble drugs via salt 
formation is well known, whereas several studies have demonstrated that cocrystals can 
provide dissolution and bioavailability advantage due to their higher solubility relative to 
the parent drug3, 5, 13-15. It has been shown that solubility of cocrystals is influenced by 
coformer solubility and if the constituents are ionizable then cocrystals exhibit a pH 
dependent solubility.13, 15-17   
Recently, several new crystalline forms of LAM were discovered and investigated 
for their solubility enhancement properties10, 11, 15.  In one case, dissolution experiments 
were carried out on LAM salts and cocrystals on the basis of which, solubilities of LAM 
crystalline forms were estimated18.  However, solubility is a thermodynamic property and 
its estimation using kinetic methods may lead to inaccurate results. This is due to solution 
mediated phase transformation of higher solubility crystalline form to lower solubility 
more stable solid form.  Furthermore, such phase transformations can be pH dependent as 
shown for salts and recently for cocrystals16, 19-216.  Hence for an accurate determination 
of solubility, it is critical to understand the solution mediated phase transformation as 






The effect of micellar concentration on cocrystal solubility and stability have also 
been investigated recently, where it is shown that beyond a critical micellar concentration 
a higher solubility cocrystal can be stabilized.  This is defined as the ‘critical stabilization 
concentration’ (CSC), beyond which the thermodynamic stabilities of cocrystal and its 
components are reversed.  For example, a higher solubility cocrystal relative to the drug 
would be thermodynamically stable above the CSC and can persist in aqueous 
suspensions.  This is due to the differential affinities of the drug and coformer to the 
surfactant22.  The LAM-NCT·H2O cocrystal investigated in this work could not be 
synthesized by reported methods, micellar solubilization has been utilized to synthesize 
this cocrystal and the existence of a CSC is investigated.   
In this work we apply the principles of solution phase chemistry to address the 
solubility and phase stability assessment by, (i) measurement and prediction of true 
thermodynamic solubilities of highly soluble cocrystalline phase, from eutectic point 
concentrations of cocrystal components, (ii) comparison of solubility dependence on pH 
of several crystalline forms of LAM, (iii) importance of pHmax on the crystalline phase 
stability and, (iv) the role of micellar solubilization and CSC on the synthesis of LAM-







Materials and Methods 
Materials 
LAM was purchased from Jai Radhe Sales, India with a purity of 99.6% w/w and was 
used as received.  All other chemicals were purchased from Sigma-Aldrich and were used 
as received.  PXRD and DSC analyses were performed on all materials to confirm phase 
purity prior to use.  LAM·H2O was prepared by suspending anhydrous LAM for a period 
of 24 hrs in water at 25±0.1ºC.  The slurry was vacuum filtered and the solid phase was 
checked by PXRD and DSC.  
 
Cocrystal and Salt Synthesis 
LAM-NCT·H2O was synthesized by reaction crystallization method (RCM).  An aqueous 
solution of 2% w/w SLS and 3.5m NCT was prepared, to which anhydrous LAM was 
added and stirred for 24hrs at ambient temperature. Cocrystalline solid phase was 
analyzed by PXRD, DSC and HPLC to confirm crystalline form and phase purity.  LAM-
SAC salt was synthesized by adding stoichiometric weight fraction of anhydrous LAM to 
a SAC solution of known concentration.  The solid phase was filtered after approximately 
24hrs and confirmed by PXRD, DSC and HPLC.  The saturated solution of LAM-SAC 
solid phase equilibrated to a pH of 3.4. 
 
Powder X-ray Diffraction (PXRD) 
PXRD patterns of solid phases were recorded with a Rigaku MiniFlex X-ray 
diffractometer (Danvers, MA) using Cu Ka radiation (λ = 1.5418 Å), a tube voltage of 30 
kV, and a tube current of 15 mA. The intensities were measured at 2θ values from 2° to 






Crystalline samples of 2-4 mg were analyzed by differential scanning calorimetry (DSC) 
using a TA instrument (Newark, DE) 2910 MDSC system equipped with a refrigerated 
cooling unit. DSC experiments were performed by heating the samples at a rate of 10 
K/min under a dry nitrogen atmosphere. Temperature and enthalpy calibration of the 
instruments was achieved by using a high purity indium standard.  Cocrystal samples for 
DSC analysis comprised of dried power isolated from slurries by vacuum filtration 
followed by air drying step. The isolated dried powder was characterized by PXRD 
before DSC analysis and HPLC for purity.  The mean result of a minimum of three 
samples is reported for each substance. 
 
Solubility Measurements 
All solubility measurements were carried out in aqueous medium at 25º±0.1C. pH was 
adjusted by adding pH 2 phosphate buffer or 0.1N NaOH. Solution concentrations of 
both components of cocrystal and salt were measured by HPLC. Solutions were 
considered to have reached equilibrium when less than 5% change in concentration was 
detected in either component of the cocrystal or salt when measured subsequently over a 
period of 24-72 hours. Solid phases were characterized by PXRD and DSC to determine 
any phase transformation at the end of the solubility measurements.  Equilibrium 
solubility measurement of LAM-SAC salt was made since salt was the stable phase 
below pHmax.  Thermodynamic solubility of LAM-NCT·H2O cocrystal was calculated 
from eutectic point concentration measurements of LAM and NCT. At the eutectic point 
solid LAM·H2O and LAM-NCT·H2O cocrystal are in equilibrium with the solution and 





Determination of Eutectic Point Concentrations and Ksp 
 
Eutectic point was established by the presence of two solid phases, LAM·H2O and LAM-
NCT·H2O cocrystal in equilibrium with the solution. The presence of solid phases was 
confirmed by PXRD and DSC.  Samples were confirmed to have two solid phases for at 
least 24-48hrs before isolating the solution and analyzing by HPLC for concentrations. 
Eutectic point was obtained from supersaturated conditions by dissolving cocrystal in 
saturated LAM solution containing excess solid LAM·H2O and from undersaturation by 
dissolution of cocrystal. By measuring the eutectic point concentration of cocrystal 
components and the solution pH, the solubility product (Ksp) value which is defined as 
the product of solution concentration of cocrystal components in their un-ionized state 
(LAM and NCT) was determined according to equation (3.1).  Similarly, Ksp for LAM-
SAC salt was calculated by measuring the solution concentrations of LAMH+ and SAC- 
according to equation (3.8) with excess solid LAM-SAC salt in equilibrium with the 
solution. 
 
Measurement of Micellar Solubilization Constant, (Ks) 
Excess solid was equilibrated in varying concentrations of aqueous SLS solutions.  
Samples were maintained at 25±0.1ºC for the duration of 24hrs. Solid phases were 
analyzed by PXRD and the solution concentrations by HPLC. 
 
High-Performance Liquid Chromatography (HPLC) 
Purity and stoichiometry of the LAM cocrystal and salt was analyzed by HPLC before 
carrying out pH dependent solubility studies and eutectic measurement studies.  Solution 








equipped with a UV/vis spectrometer detector. A C18 Atlantis column (5 μm, 4.6 × 250 
mm; Waters, Milford, MA) at ambient temperature was used to separate the drug and the 
coformer. An isocratic method with a water, methanol, and trifluoroacetic acid mobile 
phase was used with a flow rate of 1 mL/min. Sample injection volume was 20μL. 
Absorbance of the drug and coformer analytes was monitored between 210-300nm. 
Empower software from Waters Inc., was used to analyze the data. All concentrations, 
unless otherwise indicated are reported in molality (moles solute/kilogram solvent). 
 
Results and Discussion 
Solubility-pH dependence of salt and cocrystal forms 
Solubilities of the weakly basic drug LAM, a 1:1 cocrystal form (LAM-NCT·H2O), and a 
1:1 salt form (LAM-SAC) were measured under equilibrium conditions. The solubility-
pH dependence was evaluated by considering the appropriate solid solution dissociation 
equilibria of cocrystal, salt and the corresponding equilibrium constants (constituent 
ionization constant values (Ka) and solubility product (Ksp) of cocrystal and salt). The 
solubility of LAM-NCT·H2O cocrystal, composed of a weakly basic drug and a 














      (3.1) 
Ksp is the cocrystal solubility product given by 
spK
solid soln solnLAM-NCT  LAM  NCT   
spK  [LAM][NCT          (3.2) 
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<< 1, i.e., at pH where LAM is mostly in its un-ionized form, equation 
(3.5) can be written to define the cocrystal intrinsic solubility S0,cocrystal as, 
0,Cocrystal spS  K   
[LMT]T is the total concentration of LAM which is the sum of ionized and un-ionized 
species, 
T[LMT] [LAM] [LAMH ]
          (3.6)  











         (3.7) 
where  is the solubility of the unionized free base, [LAM]0,drugS 0, or intrinsic drug 
solubility. Comparing equations (3.5) and (3.7) shows that cocrystal and drug solubilities 
differ in their pH dependence. Cocrystal solubility has a weaker dependence on [H+], 
which corresponds to the square root of the drug solubility dependence.  For instance at 
[H+] = Ka 
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     (3.8) 
where Ksp is the solubility product of the salt, and is the acid ionization constant 
given by the following equilibria, 
a ,HAK
spK
solid so ln so lnLAMH SAC LAMH SAC
     
spK [LAMH ][SAC
         (3.9) 
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 are << 1, i.e., at pH values where both LAM and SAC are 
largely present as ionized species then equation (3.11) can be simplified to represent the 
intrinsic solubility of the salt, 
0,salt spS  K           (3.12) 
Thus salt solubility dependence on [H+] is also weaker than the drug solubility 
dependence and is different from that of a cocrystal.  Species without subscripts indicate 
 
solution phase and brackets represent the solution concentration in molality unless 
mentioned otherwise. The analysis presented here assumes ideal behavior with 
concentrations replacing activities in the equilibrium constants.  
 
Significance of Eutectic Point Concentrations and Calculation of Ksp 
 Since cocrystal and salt solubilities are highly dependent on the solution 
composition of their constituents, solubilities were evaluated from measurement of both 
cocrystal and salt constituent concentrations ([LAM] and [NCT] or [SAC]) and pH at 
equilibrium with solid phases according to the above equations. This is critical to ensure 
that solid phase purity did not inadvertently influence solubility measurements. Ksp of 
LAM-NCT·H2O cocrystal was calculated according to equation (3.1) by measuring 
eutectic concentrations [LAM]eu and [NCT]eu which represents the cocrystal solubility 
under non-stoichiometric conditions with solid cocrystal and drug in equilibrium with the 
solution. This Ksp value was then used to calculate the stoichiometric solubility-pH 
dependence of the cocrystal according to equation (3.5). Analytical solution 
concentrations of cocrystal components at the eutectic point are given in table 3.1. The 
eutectic constant (Keu) which is the ratio of coformer to drug eutectic concentration has 
shown to be useful in predicting cocrystal stoichiometric solubility. The ratio of [NCT]eu 
to [LAM]eu is 480.  For a 1:1 cocrystal the square root of Keu is equal to the solubility 
ratio of cocrystal to the drug.24 For LAM-NCT·H2O cocrystal, this solubility ratio is 30 
and the square root of Keu is 22. These values are reasonably close, enabling the 
estimation of cocrystal stoichiometric solubility from eutectic concentrations of cocrystal 
components. Ksp for LAM-SAC salt was calculated by measuring the solution 





SAC salt in equilibrium with the solution.  Equation  (3.11) was used to generate the 
solubility pH dependence of the salt (Figure 3.1).  The eutectic concentrations, Ksp values 
as well as cocrystal and salt solubilities are presented in Table 3.1. 
 
Table 3.1: Eutectic concentration of LAM and NCT in water, Ksp and solubility of LAM-NCT·H2O 
cocrystal and LAM-SAC salt. 
Solid Phase [LAM]eu (m) [NCT]eu (m) Ksp (m
2) S0 (m) 
LAM-NCT·H2O* (9.25 ± 0.44) x 10
-4 (4.43 ± 0.07) x 10-1 (4.1 ± 0.26) x 10-4 2.02 x 10-2 
LAM-SAC** - - (1.1 ± 0.31) x 10-5 3.26 x 10-3 
*    The average pH of [LAM]eu and [NCT]eu concentration measurement was 8.1 ± 0.15 
** LAM-SAC salt is thermodynamically stable below pH 5.0 enabling measurement of Ksp from LAMH
+ 
and SAC- concentrations according to equation (3.8). 
 
Solubility Advantage and pHmax of Cocrystals and Salts of LAM 
Figure 3.1 shows the effect of [H+] on the solubilities on LAM-NCT·H2O 
cocrystal, LAM-SAC salt and LAM·H2O.  These results reveal several important features 
regarding the solubility and stability of cocrystal and salt forms of lamotrigine. LAM-
NCT·H2O cocrystal is 30 times more soluble than LAM·H2O and LAM-SAC salt is 6 
times more soluble than LAM·H2O.  These solubility comparisons are made using the 
intrinsic solubility values of solid phases given in Table 3.2 Cocrystal and salt exhibit 
very different solubility-pH dependence as a result of the ionization behavior of their 
constituents. LAM-NCT·H2O cocrystal is the most soluble form between pH 2.7 and 7.0 
and LAM-SAC salt is the least soluble form below pH 5.0. The cocrystal with a 
nonionizable coformer follows a pH dependent behavior determined by the ionization of 
the drug (pKa 5.7) and solubility increases with pH values above pKa.  In contrast, the 





shape curve, where salt solubility is independent of pH between 2.5 and 5.0 which was 
determined graphically. Above these pH values, salt solubility increases.  
 
 
Figure 3.1: Stoichiometric solubility 2.02 x 10-2(m) of LAM-NCT·H2O cocrystal is 
represented by () and (―) represents solubility pH dependence generated using Ksp = 
4.10x10-4 m2.  Green (○) represents LAM-SAC salt solubility and red (○) represent 
[LAM] from LAM-SAC salt transformed to LAM·H2O. Solubility dependence on pH of 
LAM-SAC salt (―) and LAM·H2O (―) were generated using salt Ksp = 1.1x10
-5m2 and 
measured LAM·H2O solubility of 6.6x10
-4 m represented by (□) according to equations 
(3.11) and (3.7) respectively. 
 
It is important to note that cocrystal and salt solubility curves each intersect the 
drug solubility curve at a specific pH value, corresponding to the pHmax, also referred to 
as Gibbs pKa
2. At this pH two solids (LAM·H2O and cocrystal or salt) coexist in 
equilibrium with solution. The pHmax can be read off the graph for cocrystal at pH = 2.7 
and for the salt at pH = 5.0. This means that at pH > 2.7, cocrystal is more soluble than 
LAM·H2O whereas for the salt this increase in solubility over drug occurs at pH > 5.0.  





establishes the range of thermodynamic stability for salts and cocrystals as well as the pH 
above which either salt or cocrystal can form.   
Recently, dissolution behavior of several cocrystals and salts of LAM at pH 5.5 
and 1.0 was investigated and the data was used for solubility assessement18. We utilized 
the reported steady state dissolution concentrations to estimate the Ksp of LAM-
Methylparaben (LAM-MP) cocrystal. At the steady state LAM-MP cocrystal was in 
equilibrium with the solution.  Solubility of LAM·HCl salt was also estimated for 
comparison with other solid forms of LAM as well as to investigate the effect of [Cl-] on 
LAM·HCl salt solubility.  Ksp of LAM·HCl salt was calculated from reported solubility 
of 0.46 mg/ml at 37ºC in pH 1.2 medium12 and the solubility at 25ºC was estimated by 
using a heat of solution value of 30 kJ/mol.  A difference of  10 kJ/mol in the heat of 
solution changes the solubility by  8% and the pHmax by  1 %.  Solubilities were 
calculated under non-ionized conditions for cocrystals (pH 8) and fully ionized 
conditions for salts (pH 1 for HCl and pH 4 for SAC). The importance of phase 
transformations is also utilized to understand the trends in the reported maximum 
concentration (Cmax) achieved during the dissolution studies
18. Table containing the 
values of Cmax, steady sate concentrations, measured and estimated solubilities as well as 
initial and final pH of the dissolution medium is provided in the appendix. 
The solubility comparison of LAM crystalline forms and the dependence of 
solubility on pH are extremely critical to understand the role of (i) phase transformations 
on dissolution behavior of solid forms, (ii) role of pH on phase stability and the observed 
kinetic solubility and, (iii) role of coformer solubility on cocrystal and salt solubilities. 













with respect to  solubility and pH
2H O max
. 
Table 3.2: Ksp, solubility of cocrystals, salts and LAM·H2O, solubility ratios of cocrystals and salts relative 
to LAM·H2O, Ratio of maximum concentration (Cmax) of cocrystals and salts relative to LAM·H2O 
solubility and pHmax of solid forms. 
*   LAM-HCl salt solubility estimated in 0.1M HCl. The lowering of solubility ratio is due to common ion 
effect in the presence of 0.1M HCl. 
 
Table 3.2 shows that cocrystals can have much higher aqueous solubilities than salts and 
cocrystal solubility is highly pH dependent.  Ksp increases with LAM-NCT > LAM-SAC 
> LAM-MP.  At the pH of saturated aqueous solutions LAM-NCT·H2O cocrystal is 30 
times more soluble than LAM·H2O, LAM-SAC salt is 6 times more soluble than 
LAM·H2O and LAM-MP cocrystal has a solubility value similar to LAM·H2O. The 
solubility of the hydrochloride salt will depend on the presence of Cl- concentration.  In 
the absence of Cl- ion, the solubility of the salt is 13 times greater than LAM·H2O 
solubility. It is noteworthy that the order of Cmax (LAM-SAC > LAM-ANHYD > LAM-
NCT·H2O > LAM-MP) is not consistent with the equilibrium solubility order. LAM-
NCT·H2O cocrystal exhibits lower Cmax relative to anhydrous LAM and LAM-SAC salt 
Solid phase 
Ksp ± Std. Dev. 
(m2) 













LAM-SAC Salt (1.1 ± 0.31) x10-5 3.3 x 10-3 6 2.66 5.0 
Anhydrous LAM - - - 1.66 - 
LAM-NCT·H2O 
Cocrystal 
(4.1 ± 0.27) x 10-4 2.0 x 10-2 30 1.36 2.7 
LAM-MP Cocrystal (5.3 ± 0.47) x 10-7 7.3 x 10-4 1.1 1.24 6.4 
LAM-HCl Salt 13 - 4.6 
LAM-HCl Salt* 
(6.7 ± 0.53) x 10-5 8.2 x 10-3 





in spite of its higher solubility in water (neutral pH range) due to solution mediated phase 
transformation of cocrystal to LAM·H2O.  Results in Table 3.2 show that within this 
small series of LAM cocrystals and salts there is a wide range of pHmax values. The 
pHmax varies by about 3 units within the cocrystals, and increases with increase in 
cocrystal Ksp. This trend is similar to that observed for salts, however, for cocrystals, 
pHmax is more sensitive on the cocrystal to drug solubility ratio (by 2 pH units) as 




























        (3.14) 














       (3.15) 
when . 2sp cocrystalK S
Similar analysis for a salt of a basic drug leads to the well-known pHmax relationships




























       (3.17) 
 
This analysis demonstrates the impact of cocrystal and salt solubilities on pHmax 
and on the corresponding thermodynamic stability regions. Thus an increase in drug 
solubility by a factor of 10 will result in pHmax values of pKa – 2 for a cocrystal and pKa 
– 1 for a salt. The measured pHmax for the LAM-SAC salt is in excellent agreement with 
that calculated from equation (3.17). The pHmax of LAM-NCT·H2O cocrystal is 
calculated to be 2.7, but experimental measurement was not possible since pH could not 
be independently adjusted below pH 5.0 due to the self buffering effect of LAM. The 
LAM-SAC salt and LAM-NCT·H2O cocrystal are also shown to attain equal solubilities 
at a pH value of 7.3. This solubility is about 30 times higher than the solubility of 
LAM·H2O.  
Figure 3.2 show the solubility ratios of both LAM-NCT·H2O and LAM-SAC salt 
relative to LAM·H2O increase with increasing pH. Cocrystal solubility reaches a 
maximum value and plateaus near pH 7 while the salt solubility continues to increase 
with pH. This result in the intersection of the cocrystal and salt pH dependent solubility 
curves where the two solid forms exhibit equal solubilities at pH 7.3, while below pH 7.3 







Figure 3.2: Solubility ratio of LAM-NCT·H2O and LAM-SAC relative to LAM·H2O as a 
function of pH is shown. At pH 7.3 the cocrystal and salt solubility ratios are equal. The 
solubility ratio difference in the lower pH range of 1-4 which is relevant to the gastric and 
upper GI tract environment is highlighted by the inset. 
 
The results for LAM·H2O are in good agreement with previous reports.
9, 11, 12  
There is some discrepancy in the solubility values of the salt, with higher values 
measured in this work of 2 to 3 fold higher than those reported by Galcera10 and by 
Cheney18.  There is huge discrepancy, however, in the solubility values of the cocrystal, 
with values 30 fold higher than those reported by Cheney et al. at pH 6.2 (equilibrium pH 
of the dissolution medium after 250mins)18.  Cheney et al. used kinetic methods for their 
solubility measurements and in this work we used equilibrium methods. The source of 
this large disagreement between solubility measurements appears to be the fast 
transformation of cocrystal to the less soluble drug or the HCl salt depending on the pH.  





from LAM·H2O and LAM-NCT·H2O increases as the pH is lowered, however the 
concentration of LAM from LAM-SAC salt increased when the pH was lowered from 7 
to 5 but declined as the pH was lowered below 5. This is due to the fact that LAM is 
more soluble than LAM-SAC salt below pH 5.0.  Chadha et. al., report that LAM-
NCT·H2O transformed to LAM-H2O and the pH at equilibrium (400mins) was 6.6, while 
the LAM-SAC salt was the stable phase at equilibrium pH of 4.525.  These results are in 
excellent agreement with the pH dependent solubility behavior shown in Figure 3.1 and 
Figure 3.3. 
In contrast to the dissolution data reported in water, dissolution studies at pH 1 
showed higher LAM concentration from LAM-ANHYD, LAM-NCT·H2O and LAM-MP 
cocrystals relative to LAM-SAC.  Dissolution in pH 1 medium results in LAM-NCT·H2O 
cocrystal maintaining a higher concentration relative to LAM-ANHYD and LAM-SAC.18  
This is likely due to faster transformation of LAM to LAM·HCl due to its higher 
solubility relative to LAM-NCT·H2O cocrystal at pH 1 (Figure 3.1 and Figure 3.3).  
LAM-SAC and LAM·HCl salts have similar solubilities in water at pH 1, i.e., in the 
absence of chloride ion.  However due to common ion effect in 0.1M HCl solution, 
LAM-HCl salt has 11.4 fold lower solubility (dashed line in Figure 3.3) relative to its 
solubility in water.  Thus, LAM·HCl salt being the thermodynamically most stable form 
at pH 1, all solid forms transformed to LAM·HCl salt in the presence of Cl- during 







Figure 3.3: Solubility pH dependence of LAM solid forms calculated from Ksp values 
given in Table 3.2 and equations that describe the solubility pH dependence of cocrystals 
and salts. Common ion effect on solubility of LAM·HCl salt in 0.1M and 0.035M HCl is 
shown to simulate Cl- concentration of pH 1 dissolution medium and rat gastric 
environment respectively. 
 
Rate of transformation of metastable forms, pH of the GI environment and 
common ions present can significantly affect the bioavailability of solid forms.  It has 
been shown that the presence of chloride ion in gastric environment suppresses the 
dissolution of HCl salts26. One of the commonly used animal models for in-vivo 
estimation of bioavailability involves administering the drug to rats. The Cl- ion 
concentration in rat stomach is reported to be as high as 35mM, while pH of rat stomach 
ranges from 3-5 in fasted state27.  In this pH range and in presence of 35mM Cl- ion, 
LAM-HCl salt solubility is lowered by a factor of 4.2 relative to in water in the absence 
of Cl- (Figure 3.3). In the report where LAM-NCT·H2O cocrystal, LAM-SAC salt and 
LAM-ANHYD were dosed to Sprague-Dawley rats, the observed trend in plasma 





These trends are due to transformation of metastable forms and do not reflect the true 
thermodynamic solubility of LAM crystalline forms. Table A2.1 in appendix summarizes 
the measured cocrystal and salt equilibrium solubilities from this work as well as, Cmax, 
steady state (SS) concentrations, initial and final solid phases and pH from reported 
dissolution data. 
 
LAM-NCT·H2O Synthesis and Micellar Solubilization 
Cocrystal synthesis and screening methods have drawn a lot of attention in recent 
years.  Several methods to screen cocrystals have been published such as, synthesis from 
slurry (reaction crystallization method), grinding of cocrystal components in a mill or 
with the aid of a small quantity of solvent as well as thermal methods such as 
cocrystallization from the melt28-30.  Two methods are reported for the synthesis of LAM-
NCT·H2O cocrystal, (i) slurrying a 1:2 mixture of LAM and NCT in ethyl acetate, and (ii) 
slow evaporation of LAM and NCT solution in n-butanol31. Our attempts to synthesize 
LAM-NCT·H2O cocrystal from these reported methods did not yield a cocrystalline solid 
phase. Several other methods reported to generate cocrystals, such as, reaction 
crystallization method (RCM) where LAM·H2O was added to near saturated solutions of 
NCT, grinding of reactants in a ball mill, grinding with small amount of water as well as 
by melting of reactants were also applied. None of these attempts were successful in 
synthesizing the cocrystal. LAM-NCT·H2O cocrystal could only be synthesized by RCM 
in the presence of 2% w/w SLS aqueous solution. Further investigation was carried out to 
understand the role of SLS on the solubilization of LAM-NCT·H2O cocrystal and its 





Recently the role of surfactants in stabilizing cocrystals against solution mediated 
transformation has been reported where stabilization of the cocrystal is achieved via the 
differential solubilization of cocrystal components in micellar solution.  It is shown that 
above a critical surfactant concentration, cocrystal is the thermodynamically stable solid 
phase relative to its components. This critical surfactant concentration is referred as the 
‘critical stabilization concentration’ (CSC)22, 32. Since LAM-NCT·H2O cocrystal could 
only be synthesized from 2% w/w SLS solution, the solubility of LAM·H2O and LAM-
NCT·H2O cocrystal was measured as a function of micellar concentration to evaluate if 
SLS could be used to stabilize the cocrystal.  The stoichiometric solubility of cocrystal in 
SLS solution was estimated in a similar fashion as estimated in water, i.e., by measuring 
the eutectic concentration of LAM and NCT in SLS solution. Table 3.3 show the values 
of measured eutectic concentrations of LAM and NCT and cocrystal solubility in SLS 
solution according to equation (3.27). 







LAM H 0S   (m) 
SLS
ccS  (m) 
(5.6 ± 0.16) x 10-3 (5.1 ± 0.06) x 10-1 (4.9 ± 0.24) x 10-3 5.2 x 10-2 
 
The effect of differential solubilization on cocrystal solubility is modeled from the 
homogenous and heterogeneous reaction equilibria that describe cocrystal solubility 
product behavior and ionization of cocrystal components16, 17, 23. The relevant equilibria 
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     (3.22) 
surf[M] [C ] [CMC]    
 
The subscript aq and m denotes species in the aqueous and micellar phases respectively.  
Csurf is the total concentration of the surfactant, CMC is the critical micellar 
concentration, which is reported to be 8mM for SLS in water33. The micellar surfactant 
concentration [M] is the total surfactant concentration minus the CMC. and 
are the equilibrium constants for the solubilization of LAM and NCT respectively. 
Activities are replaced by concentrations as a first approximation applicable to dilute 





CC,Total aq mS S S  is derived by considering 
the above equilibria and mass balance on LAM and NCT,  
T aq mLAM [LAM] [LAM] [LAMH ] [LAMH ]
    m

m
    (3.23) 
T aqNCT [NCT] [NCT]          (3.24) 
From the above equilibria and equations  (3.23) and (3.24), the solubility of cocrystal as a 
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  (3.25) 
Under stoichiometric conditions, equation (3.25) can be expressed as,  
 NCTCC sp s LAM LAMHs s
a,LAMH a,LAMH
K 1 K [M]








       (3.26)  
The CMC is assumed to be constant in the concentrations and solubilization ranges 
reported here. It is common for LAM LAMHs sK K

 as the micellar solubilization negligibly 
affects the total solubility of the ionized species, unless high concentration of ionized 
species are present34-36.  Under these conditions, equation  (3.26) can be simplified to,  
 NCTCC sp s LAMs
a,LAMH
K 1 K [M]








       (3.27) 
Equation (3.27) applies to cocrystal solubility in solutions of stoichiometric 
concentrations (equimolar concentration of cocrystal components) and shows that 
cocrystal solubility increases with increasing Ksp, component micellar solubilization 
constants ( and ) and ionization of weakly basic drug LAM. From the 
unionized aqueous solubility of LAM ( ) and using the equilibria shown, the total 
drug concentration ( ) as a function of micellar concentration [M] can be 
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    
 
 
  (3.28) 
Since the micellar solubilization of LAM·H2O was measured under non-ionizing 





 LAMTotal 0 s[LAM] [LAM] 1 K [M]  
m
       (3.29) 
 
The solubilization constant Ks and ionization constant Ka values are often 
reported in the literature and cocrystal solubility can be easily calculated from a single 
measurement of cocrystal Ksp and solution pH.  However, solubility of LAM·H2O and 
NCT as a function of SLS concentration is not reported to the best of our knowledge, 
therefore Ks was experimentally measured for both LAM·H2O and NCT. From the 
equilibria shown for partitioning of LAM (or NCT) in a micelle, the total drug in solution 
is given by, 
T aq[LAM] [LAM] [LAM]         (3.30) 
Substituting the equilibrium constants in to equation  (3.30) gives, 
LAM








 ]         (3.32) 








 ]         (3.33) 
Ks for LAM·H2O and NCT were calculated from the slope according to equation  (3.32)  
and (3.33) by plotting total LAM and NCT concentrations against micellar concentrations. 
All measurements were carried out at pH 7.9 where LAM·H2O and NCT are in their non-







Table 3.4: LAM and NCT solubility as a function of micellar concentration used to calculate the 
solubilization constant (Ks) of LAM and NCT according to equations (3.32) and  (3.33). 
[M]1 







9.0 x 10-3 1.8 x 10-3 9.7 x 10-3 4.21 
2.6 x 10-2 2.9 x 10-3 3.4 x 10-2 4.28 
5.0 x 10-2 4.2 x 10-3 6.0 x 10-2 4.33 
6.0 x 10-2 4.7 x 10-3 7.7 x 10-2 4.36 
Superscripts 1 and 2 represents the micellar concentrations at which [LAM]T and [NCT]T were measured 
respectively. 
 
Figure 3.4 shows the plots used to calculate the value of Ks for LAM and NCT 
according to equations (3.32) and (3.33) by using aqueous solubility values of cocrystal 
components ([LMT]aq = 6.6 x 10
-4 (m) and [NCT]aq =  4.2 (m)). The calculated Ks values 
for LAM·H2O and NCT are 88.4m
-1 and 0.5m-1 respectively. These results are in 
agreement with the literature findings suggesting that micellar solubilization is larger for 

















aq  for NCT plotted as a 
function of micellar concentration for LAM·H2O and NCT. Subscript T and aq represents 
the total concentration in SLS solution and aqueous solubility respectively of LAM·H2O 
and NCT.  Slope represents the micellar solubilization capacity (Ks) of LAM·H2O and 
NCT by SLS. pH of solutions were in the range of 7.9 – 9.2. 
 
 
A more rigorous analysis to evaluate the parameters that govern the CSC would 
be useful not only to establish confidence in the existence of CSC but also to understand 
the conditions under which a CSC would be present and its magnitude. The mathematical 
expression that describes the CSC for a cocrystal of a monoprotic base and a non-ionic 
coformer is given by equation (3.34), which is derived by setting equations (3.27) and 
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  
        
       (3.35)
 
Inputting the values for the parameters in equation (3.35) does not yield a positive value, 
thus mathematically confirming that there is no CSC between cocrystal and LAM·H2O.  
Equation (3.35) indicates that a CSC will only exist if both, numerator and denominator 
are positive.  Thus the higher the solubilization constant of the drug ( ), or the lower 
the is, the lower the value of CSC will be.  Similarly, for a weakly basic drug (LAM), 





















, then a CSC will 
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  .  From the values of 























 were determined to be 166.0 and 941.2 respectively suggesting that 
for a cocrystal that is about 30 times more soluble than the drug, the solubilization 
constant ( ) is not high enough to yield a positive value for equation  (3.35).  Figure 
3.5 shows the solubility dependence of LAM-NCT·H2O cocrystal and LAM·H2O as a 
function of total surfactant concentration by using equations (3.27) and (3.28). The figure 
shows that the two solubility curves do not intersect in the range of surfactant 
concentrations studied. These results are in good agreement with the predicted behavior 




Figure 3.5: Effect of micellar solubilization on LAM·H2O and LAM-NCT·H2O cocrystal 
solubility. Equations  (3.27) and  (3.28) were used to generate LAM-NCT·H2O and 
LAM·H2O cocrystal solubility as a function of total SLS concentration at pH 7.9. 
 
 
The usefulness of solubilization constants is not limited to the determination of 
CSC alone. An important estimation that can be made from the value of micellar 
concentration and solubilization constants is that of cocrystal solubility in surfactant 
solutions. For example, equations (3.27) and (3.28) indicate that cocrystal and drug 
solubilities exhibit different dependencies on micellar concentration. In the case of 
cocrystal, solubility increases proportionally to [M]  while drug solubility increases 
proportionally to [M].  Assuming that ionization of drug and coformer solubilization by 











According to equation (3.36), if in a given concentration of surfactant, if the solubility of 
a drug increases by 10 fold relative to its aqueous solubility, then the cocrystal solubility 
increases by 10  fold relative to its aqueous solubility. This relationship is 
experimentally confirmed for LAM-NCT·H2O cocrystal.  
The solubility values presented in Table 3.2 and Table 3.3 show that the increase 
in cocrystal solubility in SLS relative to the increase in LAM·H2O solubility in SLS is 








=2.6.  Thus from the known 
solubilities of the drug in water and surfactant, cocrystal solubility in surfactants can be 
estimated.  The knowledge of CSC remains crucial as it can have an influence on rational 
selection of additives to modulate cocrystal and drug solubilities.  Additives with 
different solubilization capacities of cocrystal components impart thermodynamic 
stability to cocrystal phases when exposed to a solvent.  As discussed earlier using the 
example of pH dependent solubility studies, the dissolution test conditions can have a 
huge impact on the true solubility advantage of a particular solid form. Surfactants are 
common constituent of dissolution media and therefore may influence the dissolution 
behavior of cocrystals. If cocrystals are thermodynamically stable at the concentration of 
surfactant present in the dissolution medium (i.e., if there is a CSC), then the cocrystal 
thermodynamic solubility in the absence or at other surfactant concentrations may not be 
apparent leading to poor judgment of true solubility advantage. This can have 









With respect to LAM-NCT·H2O cocrystal synthesis, although a CSC does not 
exist, other mechanisms could be the driving force in cocrystal formation in 2% w/w SLS 
aqueous solution. The degree of supersaturation is a key factor that has an influence on 
cocrystallization. In a study with carbamazepine-nicotinamide (CBZ-NCT) cocrystal, 
cocrystallization reaction time was reduced from 3hrs to 3mins, when NCT concentration 
was increased in cocrystallization medium. The supersaturation of CBZ-NCT increased 
with NCT concentration and thus increased the transformation rate for cocrystal.27  
A direct measurement of LAM in NCT and 2% w/w SLS solution was not 
possible due to conversion of LAM to cocrystal in surfactant solutions above the eutectic 
point.  Figure 3.6 shows LAM concentration supersaturated with respect to the cocrystal 
in 3.5m NCT solution represented by A1 and A2 in water and 2% SLS respectively.  A1 
and A2 were estimated from K1:1 which was calculated by measuring the LAM 
concentration in NCT solutions shown by open circles (○).  Complexation constant (K11) 























    (3.38) 
From the value of K1:1, and LMT values of 6.60 x 102
LAM H 0
0S
 -4 (m) and 4.86 x 10-3 (m) in 
water and 2% SLS shown by the solid diamond (),  was estimated at 3.5m NCT 
concentration ( ) in water and 2% SLS solution (represented by A1 and A2) 





(3.38).   
 
 
Table 3.5: LAM·H20 solubility in NCT solutions used to determine K1:1 according to equation (3.37).  pH 
of all measurements were in the range of 7.9 – 8.1. 
[NCT]  
(m) 
[LAM]  ± Std. Dev.  
(m) 
- (6.60 ± 0.13) x 10 -4 
0.25 (8.36 ± 0.40) x 10 -4 
0.50 (1.06 ± 0.08) x10 -3 
1.00 (1.56 ± 0.16) x10 -3 
1.50 (2.01 ± 0.03) x10 -3 
 
From the values of LAM concentration at A1, A2, and at equilibrium with 
cocrystal in water and 2% w/w SLS solution, the calculated σ1 and σ2 values are 33.3 
and 36.9 respectively.  Although the increase in supersaturation is not large in 2% w/w 
SLS solution, the critical supersaturation value required to crystallize the cocrystal may 
exist between the values of σ1 and σ2.  Figure 3.6 indicates that cocrystal is the 
thermodynamically stable phase in water beyond the eutectic point. This was confirmed 
by phase transformation studies where the cocrystal converts to LAM·H2O in solutions of 
NCT below the eutectic point, whereas the cocrystal is the stable phase in NCT solutions 
above the eutectic NCT concentration. However, the eutectic concentration in water 







Figure 3.6: Solubility of LAM-NCT·H2O cocrystal in water (solid line) and 2% w/w SLS 
(dotted line) generated from Ksp = 4.10x10
-4m2 according to equations (3.5) and (3.27) 
and pH 7.9. (○) represents LAM concentration in NCT aqueous solutions in equilibrium 
with LAM·H2O solid phase, (□) represent eutectic concentration in water, () represent 
LAM·H2O solubility in 2% w/w SLS aqueous solution, () represent eutectic 
concentration in 2% w/w SLS aqueous solution, A1 and A2 represents the LAM 
concentrations in 3.5m NCT solution in water and 2% w/w SLS aqueous solutions 
respectively, estimated using a measured K11 value of 1.46. 
 
Other mechanisms could be responsible for cocrystallization in the presence of 
surfactants. It is well known that the rate of a chemical reaction is very sensitive to the 
nature of the reaction environment.  Many chemical reactions exhibit faster reaction rates 
in the presence of micellar surfactants, especially where one reactant is hydrophilic while 





provide an interface for a chemical interaction between reactants of vastly different 
polarities. For example, the palisades region of the micelle provides a transition zone 
between the polar and non-polar regions. This gradient in polarity serves as a convenient 
area of intermediate polarity suitable for increased reactant interactions. Another way 
micelles can facilitate reactions and reaction rates is by solubilizing a reactant with poor 
solubility, in effect increasing the concentration of reactant. In the case of LAM-
NCT·H2O cocrystal, although the degree of supersaturation of LAM-NCT·H2O in 2% 
w/w SLS is not very large relative to its value in water, a higher concentration of LAM 
(7.4 fold increase in LAM·H2O solubility) in SLS solution may facilitate a chemical 
reaction.  Thus the ability of a micellar system to solubilize a reactant can affect its action 
as a catalyst in a reaction39-41.  The role of micellar catalysis to aide cocrystallization is a 







These results indicate that cocrystals can have much higher solubilities than salts.  
Lamotrigine-nicotinamide cocrystal hydrate (LAM-NCT·H2O) is 30 times more soluble 
while lamotrigine-saccharin (LAM-SAC) salt is 5 times more soluble than LAM. The 
order of solubilities is LAM-NCT·H2O > LAM-SAC > LAM-MP, while the solubility of 
LAM·HCl salt is highly dependent on the Cl- concentration in the solution. Coformer 
solubility is a huge factor in the solubility of cocrystals and salts.  NCT solubility is over 
5000 times higher than LAM solubility while SAC and methylparaben (MP) solubilities 
are 27 and 24 times higher respectively. As a consequence, LAM-NCT·H2O is the most 
soluble form thermodynamically. The results presented here are consistent with 
previously published reports where it’s shown that cocrystal equilibrium solubility is 
influenced by coformer solubility4.  pH dependent solubility studies indicate that LAM-
NCT·H2O is the most soluble form between pH 3.0 and 7.0 and LAM-SAC is least 
soluble form below pH 5.0. In the presence of 0.1M HCl, LAM·HCl salt has the lowest 
solubility and all solid forms of LAM would therefore transform to the HCl salt. The 
eutectic concentration measurement is of critical importance in the estimation of 
cocrystal's true thermodynamic solubility. LAM-NCT cocrystal hydrated could only be 
synthesized by reaction crystallization method and in the presence of 2% SLS. The 
supersaturation states A1 and A2 are similar with respect to cocrystal solubility in water 
and 2% SLS, however LAM solubility is 8 fold higher in the presence of 2% SLS and 
therefore could facilitate cocrystal formation by providing higher concentration of 













































































































































































































































































































































































































































































































































































































































































































Figure A2.2: Calculated and 
 
 
gure A2.1: DSC thermogram of LAM-NCT·H2O cocrystal 





Figure A2.3: Solubility of LAM-NCT·H2O cocrystal in water (solid line) and 2% w/w 
SLS (dotted line) generated from Ksp = 4.10x10
-4m2 according to equations (3.5) and 
(3.27) and pH 7.9. (○) represents LAM concentration in NCT aqueous solutions in 
equilibrium with LAM·H2O solid phase, (□) represent eutectic concentration in water, 
() represent LAM·H2O solubility in 2% w/w SLS aqueous solution, () represent 
eutectic concentration in 2% w/w SLS aqueous solution, A1 and A2 represents the LAM 
concentrations in 3.5m NCT solution in water and 2% w/w SLS aqueous solutions 
respectively, estimated using a measured K11 value of 1.36. σ1 and σ2 are the LAM 
























pHmax for a cocrystal of a weakly basic drug and non-ionic coformer: 
 





















































  , when H+ >> 
a,BH
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FACTORS THAT INFLUENCE THE SPONTANEOUS FORMATION OF 







The purpose of this study was to investigate whether cocrystals form by simply 
mixing pure solid components without the need to comill.  The effects of moisture and 
temperature during storage were studied in binary mixtures where pure components were 
exposed to different levels of mechanical stress: (a) two components unmilled, (b) one 
component milled, or (3) two components individually milled. Equimolar mixtures of 
anhydrous monoclinic form III carbamazepine (CBZ) with form I nicotinamide (NCT) or 
saccharin (SAC) were stored at 25°C-75%RH, 45°C-0%RH and 45°C-75%RH.  
Transformation to cocrystal was monitored by FTIR and XRPD.  Results show that 
conversion to cocrystal occurs even when components are not mechanically stressed at all 
storage conditions within 3 months except for unmilled CBZ/SAC at 25°C-75%RH.  Free 
energy calculations from solubilities and equilibrium constants confirm that 
transformation from reactants to cocrystal is thermodynamically favorable.  Increasing 
temperature and relative humidity as well as mechanical activation by individually 
milling reactants enhances cocrystal formation. CBZ-NCT cocrystal forms faster than
 
CBZ-SAC at all storage conditions.  A metastable CBZ-SAC polymorph was detected in 
mixtures of individually milled CBZ and SAC.    
 
Introduction 
The ability to alter molecular interactions, composition, and structure in materials 
of pharmaceutical relevance using crystal engineering principles and strategies has led to 
the discovery of a large number of pharmaceutical cocrystals1-6. Cocrystals modify the 
physicochemical and pharmaceutical properties of drugs and are therefore being pursued 
as solid-state forms for drug development7-12.  Most studies have focused on cocrystal 
design and synthesis13-20. However, the spontaneous formation of cocrystals under 
conditions relevant to pharmaceutical processing or storage has not received much 
attention.    
Conversion to cocrystals in mixtures of solid reactants has been shown to occur 
by solution, vapor, melt or solid phase mediated processes.14, 21-30   Cocrystal formation in 
the solid state during comilling has been shown to be amorphous phase mediated and can 
proceed during storage after brief Comilling.29 Water present in hydrated reactants as 
well as water vapor during storage facilitates conversion to cocrystal.22, 29 Sorption of 
water and organic solvents is also known to induce transformation to cocrystal by a 
solution mediated pathway, where reactant particles take up vapor molecules and dissolve 
to generate supersaturation with respect to cocrystal.22, 31 
Anticipating conversions to cocrystal is important for pharmaceutical product 
development and performance.  In the current study, we examine spontaneous cocrystal 





conditions where cocrystal formation is not melt or solution mediated. The effects of 
moisture and temperature during storage were studied in binary mixtures where solid 
reactants were exposed to different levels of mechanical stress: (a) two reactants unmilled, 
(b) one reactant milled, or (3) two reactants individually milled. Transformation of 
equimolar reactant mixtures of anhydrous monoclinic form III carbamazepine (CBZ) 
with form I nicotinamide (NCT) or saccharin (SAC) to cocrystal was investigated.  The 
free energy of cocrystal formation determines the thermodynamic stability of cocrystal 
and was calculated from solubility and Ksp values.
21, 32   
 
Materials and Methods 
 
Anhydrous monoclinic carbamazepine form III (CBZ), nicotinamide form I (NCT) 
and saccharin (SAC) were purchased from Sigma Aldrich and were used as received. 
CBZ-NCT and CBZ-SAC cocrystals were prepared as described previously.21, 23, 29  Solid 
phases were characterized by ATR-FTIR and XRPD.   
 
Milling of reactants 
CBZ, NCT and SAC were milled individually at room temperature using the 5100 
SPEX CentriPrep (Metuchen, NJ) ball mill. About 500mg of reactant was milled for 
30min in a 3114 stainless steel vial using two stainless steel beads (0.25inch in diameter).  




Cocrystal formation was monitored during storage in four types of mixtures: (A) 
mixtures of individually milled reactants, (B) mixtures of unmilled reactants, (C) 





reactants. Unmilled reactants were sieved and the particle size used was in the range of 
63 -106µm.  Annealing of reactants was carried out at 60°C for 24 hrs immediately after 
milling. 
Mixtures of about 500 mg were prepared by mixing CBZ and NCT or SAC in 1:1 
molar ratio in a stainless steel vial using a vortex mixer. Mixtures were characterized by 
FTIR and XRPD prior to storage. Mixtures A and B were stored in desiccators 
equilibrated at 25°C-75%RH, 45°C-0%RH, and 45°C-75%RH. Mixtures C and D were 
stored at 25°C-75%RH. Cocrystal formation in all mixtures was monitored by FTIR and 
XRPD.  RH in desiccators was maintained at 0% with phosphorous pentoxide and at 75% 
with saturated sodium chloride solution.  
 
Attenuated Total Reflection Fourier Transform infra-red spectroscopy (ATR-FTIR) 
Vertex 70 (Bruker Optic Inc, Billerica, MA) equipped with a DTGS detector and 
a single bounce ATR accessory with ZnSe crystal (Pike Tech, Madison, WI) was used for 
collecting the infra-red spectra of samples. The spectra were collected in the 4000-600 
cm-1 range with 4cm-1 resolution. Each spectrum was an average of 64 co-added scans.   
Quantification of CBZ-NCT cocrystal formation during storage by FTIR was 
carried out according to a previously published procedure for CBZ-SAC cocrystal 29.  
Mixtures containing CBZ and NCT in 1:1 molar ratio, and 0%, 20%, 50%, 80% or 100% 
(w/w) CBZ-NCT cocrystal were used as calibration standards. Mixtures with 10%, 50% 
and 90% cocrystal were used as validation standards. The total mass of each standard was 
500 mg. Cocrystal used in the standards was prepared from solution as described 
previously 21, 23. CBZ, NCT, and cocrystal were individually milled for 2 minutes to 





desired proportions to prepare the standards.  Mixing was carried out in a stainless steel 
vial using a vortex mixer. The standards were characterized by FTIR. Triplicate spectra 
collected for each standard were compared to confirm homogeneity. If the standards were 
not homogenous, further mixing of components was carried out until homogeneity was 
achieved. FTIR spectra of the homogenous standards were then used to develop a 
calibration curve using the partial least square method (Quant software, Bruker Optic Inc, 
Billerica, MA). Calibration was performed by selecting the regions 3475-3435 cm-1, 
3370-3348 cm-1, 1705-1645 cm-1 and 1600-1570 cm-1 that contain characteristic peaks of 
the reactants and the cocrystal. The calibration curve was validated by using validation 
standards.  The R2 values for the calibration and validation were 0.99. 
 
X-Ray powder diffraction (XRPD) 
  
 XRPD patterns were collected in reflection mode, on a Rigaku miniflex 
diffractometer (Danvers, MA) using Cu Kα radiation (λ = 1.54Å), a tube voltage of 30kV, 
and a tube current of 15mA. Data was collected at a scan rate of 2.5°/min over a 2θ range 
of 2° to 40°.    
 
Differential scanning calorimetry (DSC) 
 
Thermal analysis of samples was carried out on a TA 2590 DSC (TA instruments, 
New Castle, DE) calibrated using indium and n-dodecane for temperature and cell 
constants.  6-8 mg sample was crimped in aluminum pans and heated at 10°C/min from 0 











 Moisture uptake studies were performed using the SGA-100 symmetrical 
gravimetric analyzer (VTI Corp. Hialeah, FL).  The instrument uses a Cahn microbalance 
(CI electronics, Wiltshire, U.K.) to monitor the sample weight and a chilled dew point 
analyzer (Edgetech, Milford, MA) to detect and control humidity in the sample chamber.  
Temperature is controlled to within 0.01°C and the instrument RH resolution is ±1%.  
About 20mg of milled or unmilled NCT was dried at 60°C for 60 min. Moisture uptake 
of dried samples was then measured at 25°C-75% and 45°C-75%RH. Equilibrium was 







FTIR spectra of crystalline reactants and cocrystals 
The crystal structure of CBZ cocrystals with NCT or SAC is characterized by 
carboxamide homodimer that is present in CBZ as shown in Figure 4.1 (graphics were 
generated using X-Seed software).33-37 NCT crystals exhibit an amide-pyridine 
heterodimer whereas SAC crystals exhibit a carboxamide homodimer, but these are not 
retained in the cocrystals.  In the CBZ-NCT cocrystal the anti -NH of CBZ hydrogen 
bonds with the carbonyl oxygen of NCT, while in the CBZ-SAC cocrystal the anti -NH 
of CBZ hydrogen bonds with the sulfonyl group of SAC16. These differences in hydrogen 
bonds are reflected in the IR spectra of these materials (Figure 4.2 and Figure 4.3). 
 
Figure 4.1: Hydrogen bonding in (a) NCT (b) SAC (c) CBZ (d) CBZ-NCT cocrystal and 






Figure 4.2 shows the IR spectra of CBZ, NCT and CBZ-NCT cocrystal.  The 
peaks at 3464 and 3157cm-1 in the CBZ spectrum correspond to the free anti -NH and 
hydrogen bonded syn -NH respectively.  A peak corresponding to the carbonyl stretch is 
observed at 1674cm-1. The spectrum of NCT similarly shows peaks corresponding to 
amide -NH (3360 and 3151cm-1) and C=O (1674cm-1) functional groups. CBZ-NCT 
cocrystal spectrum shows peaks corresponding to the amide at 3445 and 3388cm-1 and 
carbonyl at 1681 and 1656cm-1. These differences in the IR spectra of CBZ, NCT and the 
cocrystal were used to monitor transformations in reactant mixtures.  
 
Figure 4.2: FTIR spectra of (a) CBZ (b) NCT and (c) CBZ-NCT cocrystal. 
 
IR spectra of CBZ, SAC and CBZ-SAC are shown in Figure 4.3.  Analysis of  
CBZ-SAC spectrum has already been reported.29 The spectrum of SAC shows peaks 
corresponding to -NH and C=O stretch of the secondary amide at 3093 and 1715 cm-1, 





group in SAC are observed at 1332 and 1175cm-1.  The cocrystal spectrum shows peaks 
corresponding to the amide at 3498cm-1, carbonyl at 1724 and 1643 cm-1 and -SO2 at 
1327 and 1175 cm-1, due to interactions between CBZ and SAC. 
 
Figure 4.3: FTIR spectra of (a) CBZ (b) SAC and (c) CBZ-SAC cocrystal. 
 
 
Effect of mechanical activation and storage conditions on CBZ-NCT cocrystal formation 
 
Figure 4.4 shows the FTIR spectrum of CBZ/NCT mixture prepared from 
individually milled reactants and stored at 25°C-75%RH.  Peaks at 3445, 3388, 1681 and 
1656cm-1 in the spectrum of mixture at day 12 indicate cocrystal formation. XRPD 






Figure 4.4: FTIR spectra showing cocrystal formation in mixtures of individually milled 
CBZ and NCT during storage at 25°C-75%RH. Mixture (a) before storage, and (b) at day 







Figure 4.5: XRPD patterns showing cocrystal formation in mixtures of individually 
milled CBZ and NCT stored at 25°C-75%RH. Peaks used to follow the cocrystal 
formation are indicated by (■). Mixture (a) before storage and (b) at day 12; (c) CBZ-
NCT cocrystal prepared from solution; (d) Calculated from CBZ-NCT crystal structure. 
 
Cocrystal was also formed in mixtures of unmilled reactants (Figure 4.6), though 
at a slower rate than that of milled reactants e.g., 80 days versus 12 days.  Higher XRPD 
peak intensities of cocrystal at higher temperature and RH suggest that storage conditions 






Figure 4.6: XRPD patterns showing the effect of storage conditions on CBZ/NCT 
mixtures prepared from unmilled reactants. Peaks used to follow the cocrystal formation 
are indicated by (■). Mixtures (a) before storage; and after storage for 80 days at (b) 
25°C-75%RH, (c) 45°C-0%RH, (d) 45°C-75%RH; (e) CBZ-NCT cocrystal from 






Cocrystal formation during storage was quantified using ATR-FTIR.  Figure 4.7 
shows the rate of cocrystal formation in mixtures of unmilled reactants and mixtures of 
individually milled reactants stored at three conditions (a) 25°C-75%RH (b) 45°C-0%RH 
and (c) 45°C-75%RH.  These results show cocrystal formation with both unmilled and 
milled reactants. Mechanical activation of reactants by milling as well as high 







Figure 4.7: CBZ-NCT cocrystal formation in mixtures of milled reactants (■) and 
mixtures of unmilled reactants (●) stored at (a) 25°C-75%RH, (b) 45°C-0%RH and (c) 
45°C-75%RH.   
 
 
The effect of milling only one reactant, CBZ or NCT, on cocrystal formation 
during storage was also investigated.  Results show that milling CBZ enhances cocrystal 
formation while milling NCT did not have a measurable effect up to 15 days of storage 






Figure 4.8: XRPD showing the effect of milling only one component on cocrystal 
formation in mixtures during storage at 25°C-75%RH at day 15 (a) milled NCT-unmilled 
CBZ, (b) milled CBZ-unmilled NCT; (c) CBZ-NCT cocrystal from solution; (d) 
Calculated from CBZ-NCT crystal structure.   
 
The role of mechanical activation on cocrystal formation was investigated in 
mixtures of milled-annealed reactants and mixtures of milled-unannealed reactants. IR 
spectra and XRPD patterns in Figure 4.9 and Figure 4.10 respectively show that 






Figure 4.9: FTIR spectra showing the effect of annealing reactants on CBZ-NCT 
cocrystal formation during storage at 25°C-75%RH. Mixtures of (a) milled reactants at 
day 0, (b) milled-annealed reactants at day 0, (c) milled-annealed reactants at day 12, (d) 








Figure 4.10: XRPD patterns showing the effect of annealing reactants on cocrystal 
formation at 25°C-75%RH. Mixtures of (a) milled reactants at day 0, (b) milled-annealed 
reactants at day 12, (c) milled-unannealed reactants at day 12; (d) CBZ-NCT cocrystal 
from solution; (e) Calculated from CBZ-NCT crystal structure.   
 
Effect of Mechanical Activation and Storage Conditions on CBZ-SAC Cocrystal 
Formation 
 
Cocrystal formation during storage was also monitored in mixtures of unmilled 





45°C-75%RH. FTIR spectra of individually milled reactant mixtures during storage show 
new peaks at 3440 and 1650cm-1 suggesting different intermolecular interactions and 
perhaps a new phase (Figure 4.11). Peaks corresponding to cocrystal are also observed.  
XRPD patterns in Figure 4.12 show peaks at 2 theta values of 5.2, 11.3 and 23.0 
indicating the formation of a new crystalline phase. The XRPD patterns also show low 
intensity peaks at 2 theta values of 7.2, 14.2 and 28.4 characteristic of CBZ-SAC 
cocrystal.  Transformation of the new phase to cocrystal was observed after seeding the 
mixed phase with CBZ-SAC cocrystal prepared from solution. This transformation 
indicates that the new phase is less stable than the cocrystal prepared from solution.  The 
IR spectra and XRPD patterns suggest that this new form is different from a polymorph 
of CBZ-SAC cocrystal recently reported.38 In the case of unmilled reactant mixtures the 






Figure 4.11: FTIR spectra showing the effect of storage condition on CBZ/SAC mixtures 
prepared with milled reactants. Peaks used to follow the cocrystal formation are indicated 
by (■) and of new phase are indicated by (□). Mixtures (a) before storage; and after 
storage for 80 days at (b) 25°C-75%RH, (c) 45°C-0%RH, (d) 45°C-75%RH; (e) CBZ-






Figure 4.12: XRPD showing the effect of storage conditions on CBZ/SAC mixtures 
prepared with milled reactants. Peaks used to follow the cocrystal formation are indicated 
by (■) and of new phase are indicated by (□). Mixture (a) before storage; and after 
storage for 80 days at (b) 25°C-75%RH, (c) 45°C-0%RH, (d) 45°C-75%RH; (e) CBZ-






The effect of milling only one reactant was investigated for CBZ/SAC mixtures as 
well. The mixture behaved similar to the unmilled reactants. Table 4.1 summarizes 
cocrystal formation in mixtures of CBZ/NCT and CBZ/SAC during 3 months of storage.  
Under all storage conditions studied, CBZ-NCT cocrystal formation was faster than 
CBZ-SAC. Mechanical activation of reactants as well as higher temperatures and relative 



















25°C-75%RH + + + 




45°C-75%RH + + + 
25°C-75%RH - +, * +, * 




45°C-75%RH * +  * 
+, * 
25°C-75%RH - + + 
45°C-0%RH - + + 
CBZ/NCT 
Unmilled reactants 
45°C-75%RH + + + 
25°C-75%RH - - - 
45°C-0%RH - - + 
CBZ/SAC 
Unmilled reactants 
45°C-75%RH - + + 








Spontaneous cocrystal formation without milling reactants indicates that cocrystal 
is the thermodynamically stable phase.  The requirement for spontaneity is a negative free 
energy change. The free energies for cocrystal formation can be evaluated from 
solubilities or equilibrium constants by a method similar to that described for    
solvates.39, 40  The free energies for CBZ-NCT and CBZ-SAC cocrystal formation from 
the reactant mixtures in the solid-state were calculated to be -4.8 kJ/mol and -5.1 kJ/mol, 
at 25°C according to the thermodynamic cycle illustrated in Table 4.2.  Ksp and solubility 
values in terms of concentrations measured in ethanol were used to calculate free 
energies. For a more rigorous calculation activities should be considered, however, 
solution complexation under these conditions is negligible and Ksp describes the 
experimental solubility behavior. 21  These negative free energies confirm the spontaneity 
of the process.  While the free energies of formation are comparable for the two 
cocrystals, rates of formation for CBZ-NCT were faster than for CBZ-SAC, suggesting 
that factors other than thermodynamics such as diffusivities, molecular mobility, 






Table 4.2: Chemical equilibria considered for free energy calculations 
SA and SB are the solubilities of the drug and ligand in the solvent. Ksp is the solubility product of the 
cocrystal.  The solubility in concentration units (M) are: CBZ(III)=0.108, NCT(I)=0.841 and SAC=0.189; 
The Ksp values in concentration units (M
2) are: CBZ-NCT=0.0129 and CBZ-SAC=0.0026.  All 
measurements were carried out at 25°C.21, 32 
Equation # Equilibrium reaction Free energy of reaction 
4.1 A(solid)   A(soln) ΔG° = -RT ln(K) = -RT(ln SA) 
4.2 B(solid)    B(soln) ΔG° = -RT ln(K) = -RT(ln SB) 
4.3 A(soln) + B(soln)    AB(solid) ΔG° = -RT ln(1/Ksp) 
Adding equations 4.1, 4.2 and 4.3 yields 














RT ln  
 
Cocrystal formation rates increased with higher relative humidities and 
temperatures.  It is important to note that cocrystal formation occurs in unmilled reactants 
at room temperature. Previous studies have shown that vapor sorption of reactants can 
lead to deliquescence and generate the supersaturation necessary for cocrystal  
Formation.22, 31 This has been shown for CBZ/NCT mixtures at high RH (98%) where 
moisture sorption occurs due to deliquescence of NCT.22  Results of the present study 
show low moisture uptake of NCT (< 0.3%) at 25°C-75%RH and 45°C-75%RH and 
suggest that cocrystal formation is not deliquescence-mediated under these conditions.  
The deliquescence relative humidity of NCT at 25°C and 45° is above 85%.  Furthermore, 
CBZ, SAC, CBZ-SAC and CBZ-NCT do not deliquesce under these conditions22 .  Thus 
low levels of moisture uptake can facilitate conversions to cocrystal.   
Eutectic melt-mediated cocrystal formation at room temperature has been 





cocrystals of CBZ with carboxylic acids at temperatures above 85°C14. Thermal analysis 
of 1:1 CBZ/NCT and CBZ/SAC mixtures did not show an endothermic event 
corresponding to a melt below 85°C and therefore cocrystal formation is not melt-
mediated under these conditions.  Solid-vapor interactions due to sublimation of reactants 
have also been shown to form cocrystals.25 While it is not clear the extent to which 
sublimation plays a role in our studies, physical contact between the reactants was 
necessary for cocrystal formation.   
 Solid state mediated cocrystal formation has been reported to occur by disorder or 
amorphous phases generated by comilling or melt quenching.29, 47  Cocrystal formation 
from amorphous phases has been shown for CBZ-SAC, CBZ-NCT, as well as for some 
cholic acid complexes.29, 47, 48  Rates of cocrystal formation were also shown to increase 
with increasing temperature and relative humidities during storage.  In the present study, 
individually milling reactants increased cocrystal formation rates during storage.  Faster 
cocrystal formation rates may be due to disorder and higher surface areas generated by 
milling reactants.  Disordered regions were not detectable by XRPD or DSC, however 
annealing reactants prior to mixing slowed the rate of cocrystal formation. Small 
percentage of disorder created by milling, as little as 2%, has been shown to increase 
reactivity as in the chemical degradation of metoclopramide by Maillard reaction, while 
annealing decreased reactivity.49 
Mechanical activation of only one component in reactant mixtures also affects 
cocrystal formation rates. CBZ-NCT cocrystal formation is faster in mixtures of milled 
CBZ/unmilled NCT relative to mixtures of unmilled CBZ/milled NCT. Milling either 





be associated with the molecular mobility and glass transition temperature of reactants 




Conversion of solid reactants to cocrystal occurs spontaneously even when 
reactants are not mechanically stressed. Free energy calculations indicate that 
transformation of solid reactants to cocrystal is favorable under ambient conditions.   Our 
results show that low levels of moisture uptake and temperatures encountered during 
pharmaceutical processing and storage produce cocrystals. Mechanical activation of 
individual reactants increases the kinetics of cocrystal formation in binary mixtures of 
reactants. These findings have important implications in formulation development, 
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                                         CHAPTER 5 
 
 
FREE ENERGY CALCULATIONS FOR COCRYSTAL FORMATION FROM 





The purpose of this work is to present mathematical models that describe 
cocrystal thermodynamic stability and the driving force for cocrystal formation from its 
components in the solid state, from directly measurable and derived thermodynamic 
parameters. Based on the thermal properties of cocrystal reactants, thermodynamic cycles 
were developed and used to express the Gibbs free energy of formation. The Gibbs free 
energy of formation for several cocrystals was calculated from melting point (MP), heat 
of fusion (ΔHf), entropy of fusion (ΔSf) and from the heat capacity (ΔCp) difference of 
the solid and liquid state of the components. Cocrystals with MP between the two 
components or with lower MP than either component were analyzed using the derived 
equations. Standard and modulated differential scanning calorimetry (DSC) was used for 
measuring the thermodynamic quantities. The Gibbs free energy of formation ( ) at 
the melting point of the lower melting component, A, changes as a function of the 
difference in melting point between the higher melting component and the cocrystal 







fT T T  
 




G values, suggesting 
that solid to solid transition of pure crystalline components into cocrystals is not 
thermodynamically favored. Cocrystals with a smaller value of ( ) usually 
resulted in large negative values of suggesting that the spontaneous cocrystal 
formation from pure crystalline components is thermodynamically favorable. This has 
important implications for assessing thermodynamic stability in pharmaceutical 













In recent years, pharmaceutical cocrystals have become an emerging class of 
crystal forms that is considered during the early phase of drug development.1-3  
Cocrystals are attractive alternative solid forms as they have the ability to alter the 
physico-chemical properties of the active, leading to desirable biopharmaceutical 
outcome.  There are several reports that describe the solute-solvent interactions such as 
complexation, aqueous solubility, solubility dependence on pH, micellar solubilization 
behavior, dissolution behavior and bioavailability advantages of cocrystals.2, 4-10 Since the 
application of cocrystals as possible pharmaceutical solid forms is still emerging, a lot of 
research is directed towards the discovery of new cocrystals.  Several reports have been 
published on the methods that were successfully applied to discover new cocrystals.  
Some of the most commonly reported techniques to synthesize cocrystals are grinding of 
the cocrystal reactants in a mill, grinding of reactants with the aid of solvent, reaction 
crystallization method and thermal methods such as cocrystallization from melt.11-15  




intention to discover new cocrystals, there is evidence showing that cocrystal formation 
can occur inadvertently from solutions of cocrystal constituents, mixtures with 
deliquescent additives and from eutectic melts.3, 5, 16  In one instance, spontaneous 
cocrystallization from reactants has been documented where the cocrystal components 
when stored as physical mixtures converted to cocrystals without external energy input.  
It was observed in this study that the transformation was truly a solid to solid conversion 
of reactants to cocrystals, as no other mechanisms such as eutectic melt, water adsorption 
by reactants or amorphous phase mediated cocrystallization were determined to be 
responsible for cocrystal formation.17  This spontaneous formation of cocrystals from its 
constituent reactants is the result of differences in the energetics between the cocrystal 
and its reactants in the solid state resulting in the negative free energy of formation 
( ).  However, there is no mathematical treatment available to calculate ofG
o
fG  of 
formation for cocrystals from its reactants using the thermodynamic properties of the 
solid reactants. 
The thermodynamic driving force for racemic compounds from its enantiomers 
has been previously described, where a binary phase diagram generated from fusion data 
has been used to describe the nature of racemic compound, racemic conglomerate or a 
pseudo-racemate.18, 19 In the case of racemic compounds the thermodynamic driving 
force for the formation of racemates is provided due to the differences in thermodynamic 
properties of the racemates and enantiomers. Likewise, the differences in the 
thermodynamic properties of cocrystal and its components can be used to understand the 
driving force for the formation of cocrystals from solid reactants.  This type of 




chiral pharmaceuticals.20, 21 Although some studies on the thermodynamics of cocrystal 
formation have been reported,22, 23 an investigation of this nature where the 
thermodynamic driving force for a solid to solid cocrystal transformation is studied has 
not been reported to the best of our knowledge.  Cocrystals differ from racemates in their 
chemical composition, such that unlike racemates, the constituents of cocrystals are often 
entities of different chemical class with widely different fusion properties. Due to this 
difference, the thermodynamic cycles developed by Jacques et. al., to calculate the free 
energy of formation of racemates cannot be applied to cocrystals.  The specific aim of 
this work is therefore to, (i) Investigate the thermal properties of cocrystal and its 
components to generate a binary phase diagram, (ii) Categorize cocrystals in groups 
based on it thermal properties relative to their components and, (ii) Develop 
thermodynamic cycles that are useful in calculating the driving force for cocrystal 
formation from its components.  Cocrystal of carbamazepine (CBZ) and nicotinamide 
(NCT) is used as the model system to generate the temperature-composition phase 
diagram.  Similar to racemic compounds, a binary phase diagram can be used to predict 
the stability of the cocrystals. However, unlike racemic compounds melting point alone is 
not sufficient to predict the cocrystal stability, rather the magnitude of the difference in 
the melting point of the cocrystal and its components will govern the relative stability of 
the phases.  This is discussed in detail in this chapter.   
Several cocrystals are selected for investigation in this work and theoretical 
models to calculate the free energy of formation are developed for two categories of 
cocrystals, (i) cocrystals with melting point in between the melting point of its 











The stability of a cocrystal can be defined by the molar Gibbs free energy change (ΔGº) 
for the reaction where solid to solid transformation corresponding to the crystals of the 
two reactants A and B occur to yield cocrystal AB.  The reaction can be depicted as, 
     As  +  Bs    ABs   (5.1) 
The subscript ‘s’ refers to the crystalline solid state of the cocrystal and its reactants.  For 
spontaneous cocrystal formation the free energy change associated with this reaction 
must be negative.  The Gibbs free energy of formation ofG  can be expressed as a 
function of the corresponding molar enthalpy of formation 0 fH and the molar entropy of 
formation 0 fS . 
     0 0    of fG H T S f    (5.2) 
The thermodynamic quantities in equation (5.2) can be determined from calorimetric data. 
Two types of cocrystal systems are discussed, (a) cocrystal melting point is in between 
the melting point of its reactants, ( A C Bf fT T T  f
B
) and, (b) cocrystal melting point is lower 
than the melting point of both its reactants ( C Af fT T T  f ).  These two types of systems 
are shown in Figure 5.2 and Figure 5.3 for cocrystals of 1:1 stoichiometry.  Superscripts 





         
  
          (a)      (b) 
Figure 5.1: Theoretical phase diagrams of cocrystals; (a) Cocrystal melting point between 
the melting point of its components; (b) cocrystal melting point lower than the melting 
point of its components. AfT , 
B
fT  and 
C
fT  are the melting points of cocrystal constituents A 
and B and cocrystal respectively. 
 
Jacques et al. developed an approach based on the differences in the 
thermodynamic quantities between racemic compounds and their corresponding racemate 
to calculate the enthalpy and entropy of formation, from which free energy of formation 
can be calculated.20 In our work the thermodynamic cycles (TDC) are developed for 
cocrystals, which unlike racemic compounds have components that are chemically 
different and have different melting temperatures and melting enthalpies.  Figure 5.2 and 
Figure 5.3 show TDCs for cocrystals classified into two different categories shown in 
Figure 5.1. 
When the reaction shown by equation (5.1) occurs at the melting point of the 




cocrystal reactants are completely immiscible in the solid state i.e.,  mSH = 0 and the 
enthalpy of mixing in the liquid state is mlH , equations can be derived to calculate the 
free energy of cocrystal formation.  For a random mixture of compounds in the liquid 
state, i.e., when the entropy of mixing is ideal, mlS  can be expressed as, 
( ln lnml A A BS R )B        
For a 1:1 cocrystal the ideal entropy of mixing value will be, 
    1 1ln 2 5.76mlS R Jmol K
     (5.3) 
Using the TDC shown in Figure 5.2, enthalpy and entropy of formation expressions were 
derived which were then used to define the expression for the Gibbs free energy of 








Case 1 ( A C Bf f fT T T  ): 
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Figure 5.2: The enthalpy changes during various steps of a TDC involving cocrystal 
reactants A, B and cocrystal C, when cocrystal melting point is between its constituents.  
ΔHf, Cs, CL and Tf represent the enthalpy of fusion, heat capacity of the solid and liquid 
and fusion temperature respectively.  Subscripts l and s denote the liquid and solid 
phases. ΔHm and ΔHº denote the enthalpy of mixing and the enthalpy of formation 








From the TDC shown in Figure 5.2 enthalpy of formation at fusion temperature of lowest 
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S S L S f f fA BT
f f
T T
S (C C )(ln ) (C C )(ln ) S S S R ln 2
T T
             (5.5) 
Assuming that the contribution of heat capacity terms in equations (5.4) and (5.5) 
are negligible, and substituting the enthalpy and entropy of formation in equation (5.2) 







0 B B A C C A A
f f f f f f fT
G S (T T ) S (T T ) T R ln       2 mlH+     (5.6) 
Equation (5.6) can be further simplified by applying Walden’s rule and taking average 
entropies of fusion of component A and cocrystal, 
A
f
0 B C A
f f fT
G S(T T ) T R ln 2 H       ml       (5.7) 
Equations (5.6) and (5.7) can be used to calculate the free energy of formation of 
cocrystal at the fusion temperature of the lower melting species. Equation (5.7) indicates 
that the difference between the melting temperature of the higher melting component (B) 
and cocrystal will influence the sign as well as magnitude of ofG of formation. The 
entropy of mixing term always favors cocrystal formation while the enthalpy of mixing 
can be negative, positive or zero.  The heat of mixing depends on the molecular 
interactions between the cocrystal components.  The value of  is negative when 
there is bond formation in the reactant melt, positive if the mixture is not ideal and no 
molecular interaction occurs, while a ΔH
m
lH




in the liquid state.  In the case of cocrystal formation, the value of must be negative 
due to interactions between the cocrystal components.  These interactions are most likely 
due to the hydrogen bond formation between the reactants.  
mix
lH
Table 5.1 contains the 





Case 2 ( C A Bf f fT T T ): 
In the case when the cocrystal fusion temperature is below the fusion temperature 
of both its components, the TDC shown in Figure 5.3 can be used to derive the relevant 
equations to calculate the free energy as shown. 
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Figure 5.3: The enthalpy changes during various steps of a TDC involving the cocrystal 
reactants A and B and cocrystal C, when cocrystal melting point is lower then that of its 
components.  ΔHf, Cs, CL and Tf represent the enthalpy of fusion, heat capacity of the 
solid and liquid and fusion temperature respectively.  Subscripts l and s denote the liquid 
and solid phases. ΔHm and ΔHº denote the enthalpy of mixing and the enthalpy of 





From the TDC shown in Figure 5.3, enthalpy of formation at fusion temperature of 
component C ( ) and the entropy of formation ( ) can be derived.  Assuming 
that the contribution of heat capacity is negligible, the expression to calculate the free 

















0 A A C B B C C
f f f f f f f mT
G S (T T ) S (T T ) T R ln 2 H          l
l
   (5.8) 
By applying Walden’s rule equation (5.8) can be further simplified to, 
C
f
0 A B C C
f f f f f mT
G S (T T 2T ) T R ln 2 H            (5.9) 
According to the Walden’s rule, for non-spherical rigid molecules the ratio of heat of 
fusion to the fusion temperature is roughly constant at around 50-60 JK-1 mol-1, more 
specifically a value of 56.5 JK-1 mol-1 is assigned. However, spherical or close to 
spherical molecules are not bound by this rule because they often yield anomalously low 
values of fS . Neither are flexible molecules, with elements of structure that can assume 
different conformations in the liquid state. For example, in a set of 739 compounds 
studied by Gilbert, two subsets were generated, one with 358 rigid compounds and the 
other with 381 flexible compounds21. It was found that there was a strong correlation 
between fS and  fH with flexible molecules tending to yield higher values of fS for 
a given  fH . Thus Walden’s constant although a good first approximation to estimate 
the entropy of fusion must be carefully inspected on a case by case basis. 
Equation (5.9) indicates that if the enthalpy of mixing is zero, then if  is greater 
than the sum of  and  by a factor of 2.2 than  will be negative.  Thus the 
melting point of cocrystal relative to its components is a good indicator of solid to solid 
















temperature would be of great interest.  Expressions for ofG  at a temperature T are 
derived from the TDCs shown in Figure 5.2 and Figure 5.3 and are given by, 
0 A A B B C C







H     (5.10) 
By taking average entropies, equation (5.10) can be expressed in terms of  and 















G G (T T)( S R ln 2) H              (5.11) 
C
f
0 0 C C
T f f fT
G G T S (T T)(R ln 2) H              (5.12)
 
According to equations (5.11) 0TG  is likely to remain negative over a wider temperature 
range below the cocrystal melting temperature i.e., for the case when . 
When  has a small negative in equation 
A C






TG (5.11), then the sign of  may become 
positive depending on the sign and magnitude of heat capacity and entropy terms.  This is 












G (5.12) as well 






Materials and Methods 
Materials 
GBPL (97+% purity) was purchased from Waterstone-Technology, LLC. Carmel IN.  All 
other chemicals were purchased from Sigma-Aldrich and were of 99+ % purity and were 
used as received.  Materials were characterized by X-Ray powder diffraction (XRPD) 
and DSC prior to use.  All the new forms were synthesized according to reaction 





The cocrystals were synthesized according to the reaction crystallization method 
previously described by where cocrystals were precipitated from near saturated aqueous 
solutions of the higher solubility component.14  The slurry was left to stir for 12-24 hours 
followed by filtration of the crystallized solid using a vacuum filtration assembly.  The 
filtered material was air dried and the solid phase confirmation and purity analyses were 
carried out by PXRD, DSC and HPLC. 
 
X-ray Powder Diffraction (XRPD) 
XRPD was used to identify solid phases after to determine cocrystal formation.  XRPD 
patterns of solid phases were recorded with a Rigaku MiniFlex X-ray diffractometer 
(Danvers, MA) using Cu Ka radiation (λ = 1.5418 Å), a tube voltage of 30 kV, and a tube 
current of 15 mA. The intensities were measured at 2θ values from 2° to 30° with a 
continuous scan rate of 2.5°/min.   
 
Thermal Analysis 
Crystalline samples of 2-4 mg were analyzed by differential scanning calorimetry (DSC) 
using a TA instrument (Newark, DE) 2910 MDSC system equipped with a refrigerated 
cooling unit. DSC experiments were performed by heating the samples at a rate of 10 
K/min under a dry nitrogen atmosphere. Temperature and enthalpy calibration of the 
instruments was achieved using a high purity indium standard. Standard aluminum 
sample pans were used for all measurements.  All samples were measured in triplicates 
with standard deviation less than 5%.  Cocrystal samples for DSC analysis comprised 




reactants.  These crystals were isolated from solution, washed, and characterized by X-
Ray diffraction before DSC analysis.  Heat capacities were measured by modulated 
differential scanning calorimetry (MDSC).   
 
Results and discussion 
 
Thermal data of several cocrystals that have melting point in between the melting 
point of its components is listed in Table 5.1.  The table shows the free energy of 
cocrystal formation at the temperature of melting of the highest melting components as 
well as at 25ºC.  It is apparent that the values of free energy of formation are more 
negative at the melting temperature of the highest melting component for all cocrystals.  
However at room temperature some cocrystals have larger value of free energy of 
formation while others have negative value.  This difference is due to the contribution of 
the enthalpy of mixing in the liquid state, while we assumed that this mixing enthalpy is 














































































































































































































































































































































































































































































































































































































































































































































































































































































































discussed previously this assum
 shows the free energy of formation as a function of temperature difference 
ponents.  However the analysis shown in figure assumes that the 
 mixing in the liquid state is negligible or that the mixing is ideal.  As 
ption does not apply to cocrystals since the components 
are chemically different, however the figure implies that in the absence of heat of mixing 
the dependence of free energy on the temperature difference of cocrystal components 
would be linear.  These results are similar to the findings for about 25 racemic species 






Figure 5.4: Free energy values of cocrystals against the difference between the fusion 
temperature of higher melting component and cocrystal for the case when the cocrystal 
melting point is between the melting point of its components ( A C Bf f fT T T  ). 
 
Table 5.2 summarizes the thermal behavior of cocrystals and its components for 
the case where cocrystal melting point is below that of its components ( ).  
Equation 
C A
f fT T T 
B
f
(5.9) is used to calculate the free energy of cocrystal formation for this case. It 
is observed that when is calculated and used in equation mlH (5.9) then the free energy 
of formation of all cocrystals belonging to this category is negative.  However, if we 
assume that is negligible then the value of free energy for all cocrystals is positive. 
These results are similar to the previous investigation using racemic species
m
lH
22.  This 
implies that these cocrystals can form from the melt or the solutions phase, however their 
spontaneous crystallization from the reactant in the solid state is not thermodynamically 
favorable.  It is evident from equation (5.9) that for 0TG  to be negative the fusion 
 
temperature of the cocrystal must be 2.1 times the sum of the fusion temperatures of its 
components.  When  is close to zero, the driving force for spontaneous cocrystal 
formation would be small and the kinetic factors such as temperature, disorder in material 




(5.9) are used to study the dependence of difference of fusion temperature on 
0
TG  as 
shown in Figures 5.4 and 5.5. The entropy of mixing term is always negative and will 
contribute towards cocrystal formation suggesting that the entropy of mixing of the melt 





































































































































































































































































































































































































































































    
igure 5.5: Free energy values of cocrystals listed in Table 5.2 against the difference 
between the sum of fusion temperatures of cocrystal components and twice the fusion 
temperature of cocrystal for the case when the cocrystal melting point is lower than the
melting point of its components ( f f fT T 
f
calcu
of our knowledge.  Further work 




Investigation of all cocrystals listed in this chapter for spontaneous crystallization 
rom its reactants is beyond the scope of this work.  This type of theoretical formalism to 
late the free energy of cocrystal formation is developed for the first time to the best 
will be needed to experimentally test the models with 
s, investigate possible exceptions and develop theoretical refinement. 
owever, we investigated the thermal behavior of CBZ-NCT cocrystal in detail which is 
ed in the following sections. This investigation provides detailed insights to
several stages through which the reaction proceeds when exposed to temperatures up to 
 
 
the melting temperature of the highest melting component.  The solid-liquid phase 
equilibrium data for the CBZ/NCT system is shown in Figure 5.6 in the form of 
temperature-composition phase diagram. The plot shows the formation of a 1:1 CBZ-
NCT cocrystal with congruent melting point (represented by B) and the two eutectic 
melting points, E1 and E2.  The eutectic compositions as well as the experimental and 
calculated eutectic temperatures are reported in Table 5.3.  Figure 5.6 indicates that the 
melting point of CBZ decreases with the addition of NCT until it reaches a minimum 
value at E1, which is the eutectic between CBZ and the cocrystal.  On further addition of 
NCT, the melting point rises slightly to a maximum value at B.  At the point B, the 
components of the solid and liquid phases are identical.  This maximum temperature is 
the congruent melting temperature of the CBZ-NCT cocrystal.  Beyond the congruent 
melting point, a further increase in the NCT composition causes a decrease in the melting 
point of the physical mixture approaching a second minimum temperature E2, which is 
the eutectic between NCT and cocrystal.  The lowering of CBZ and NCT melting points 
shown in the binary melting phase diagram in Figure 5.6 is generated by plotting the 
melting temperature of pure components (CBZ and NCT) recorded by DSC as a function 
of composition of the mixture.  The experimental points were compared with the 







Figure 5.6: Phase diagram showing the thermal behavior of CBZ/NCT binary mixture.  
A, B and C are the melting points of CBZ, NCT and CBZ-NCT cocrystal respectively,   
the theoretical thermodynamic eutectic temperature is represents by (-----), E1 and E2 are 
the observed eutectic temperatures between CBZ and cocrystal and between NCT and 
cocrystal respectively. (●) represents the experimental melting points and (―) is the 










     (5.13) 
Where, A is the mole fraction of the component A in the mixture melting at 
temperature . and  are the enthalpy and the temperature of fusion (in Kelvin) 






-1mol-1).20  The 
part of the phase diagram where the solid phase consists of the cocrystal is a function of 





of the mixture can be calculated for a mixture of known composition using the Prigogine-





2 H 1 1
ln 4 (1 ) ( )
R T T
        (5.14) 
Where, χ is the mole fraction of one of the components in the mixture whose melting 







Table 5.3: CBZ/NCT binary mixture eutectic data showing the eutectic compositions, experimental and 
calculated eutectic temperatures. 
Composition 
Mole fraction 





Eutectic 1 0.6 125 129.1 
Eutectic 2 0.03 155 159.8 
 
 
From the data in Table 5.3 and Figure 5.6, it is evident that the Schröder-Van Laar and 
Prigogine-Defay equations over predict the eutectic temperatures.  For the eutectic points, 
E1 and E2 the calculated temperatures are 4.1 and 4.8°C above the experimental 
temperatures respectively.  These temperature differences are presumably due to some 
degree of non ideality in the molten state of mixtures. A mixture is considered to behave 
ideally in the liquid state if the enthalpy of mixing ( mixH ) were equal to zero.  The 
enthalpy of mixing is calculated using the following equation,26    
exp 1 2
mix 1 fus 2 fusfusH H H H           (5.15) 










From the values of the enthalpies of fusion of cocrystal and cocrystal constituents, 
various thermodynamic parameters can be estimated to understand the crystallization 
behavior from the melt, specifically the eutectics and the interaction between the 
components forming the cocrystal can be calculated.  If a eutectic is a simple mechanical 
mixture of two components involving no enthalpy of mixing or any type of association in 
the melt, then the enthalpy of eutectic melt is given by,  
eu 1 2
fus 1 fus 2 fusH H     H    (5.16) 
where,   and are the mole fraction and enthalpy of fusion of components 1 and 2.fusH
26 
A mixture is considered to behave ideally in the liquid state if the enthalpy of mixing 
( ) is equal to zero.  However, mixtures in the liquid state may not behave ideally.  
This is due to the fact that the energy of intermolecular homomeric interactions in the 
liquid or solution state is different from the energy of corresponding heteromeric 
interactions.  Depending on whether heteromeric interactions are stronger or weaker than 
the homomeric interactions there would be either evolution or absorption of heat involved 
resulting in either an exotherm or an endotherm.
miH x
20 The experimental and calculated 
eutectic temperatures are shown in Table 5.3. The deviation in the experimental and 
calculated temperature values of the two eutectics as well as the negative enthalpies of 
mixing is due to the heteromeric interaction between CBZ and NCT, most likely due to 
the hydrogen bond formation in the molten state. The formation of intermolecular 
hydrogen bonds causes the liberation of heat resulting in lower experimental values of 
enthalpy of fusion relative to the calculated values.  The cocrystal formed between the 
two components follows the reaction scheme given below. 
Amelt + Bmelt  ABmelt ABsolid  
 
This simple reaction scheme can be easily delineated from the DSC thermograms shown. 
     
Figure 5.7: DSC thermogram representing the thermal events of CBZ/NCT mixtures with 
increasing mole fraction of NCT in the mixtures. Thermal event A is the eutectic 
endotherm between the CBZ and NCT (~108°C), B is crystallization of CBZ-NCT, C is 
eutectic between the cocrystal and NCT (~127°C) and D is the exotherm due to continued 
cocrystal formation, E is the eutectic between cocrystal and CBZ (~155°C), F is melting 
of the cocrystal (~160°C) and G is melting of CBZ.   
 
 
Thermal event A is the first eutectic event which is between the cocrystal components, 
CBZ and NCT in the physical mixture.  Event B pertaining to the cocrystallization from 
the eutectic melt was confirmed by halting the DSC immediately after this crystallization 
exotherm B was completed (at 120°C) and analyzed by PXRD (Figure 5.8).  CBZ-NCT 
cocrystal can be identified by PXRD, while the un-reacted components are still present in 
the mixture leading to the thermal events observed in Figure 5.7. These thermal events 
were confirmed by performing DSC experiments with mixtures of pure cocrystal and 






Figure 5.8: PXRD showing the formation of CBZ-NCT cocrystal upon completion of the 
thermal event B (and before event C) in Figure 5.7. 
 
 
Figure 5.9: DSC thermograms of CBZ-NCT cocrystal and NCT mixtures. Thermal events 






Figure 5.9 indicates that the eutectic between NCT and cocrystal is between 0.9 and 1.0 
mole fraction of NCT in the mixture as predicted by equations (5.13) and (5.14). 
Cocrystal melting is shown by the thermal event B, which approaches the melting 
endotherm of the pure cocrystal with increasing mole fraction of the cocrystal.  
 
Figure 5.10: DSC thermograms of CBZ-NCT cocrystal and CBZ mixtures.  Thermal even 
A is the eutectic between CBZ and CBZ-NCT cocrystal and B represents cocrystal 
melting. 
 
Figure 5.10 shows the DSC thermograms of mixtures of CBZ and cocrystal.  A eutectic 
halt can be observed at about 155ºC. The endotherm associated with the melt of the 
cocrystal shifts to that of the pure cocrystal melting endotherm with higher proportion of 








Hot stage microscopy (HSM) 
HSM was performed to confirm the results seen by the DSC.  Figure 5.11 shows the hot 
stage polarized light microscopic images of the CBZ/NCT mixture.   





Figure 5.11: HSM showing the thermal events of CBZ/NCT mixture upon constant rate 
heating.  A: small melting at 108°C due to the eutectic event A as seen in the DSC; B: 
New crystals growing due to event B shown in the DSC; C: Melting at 127°C due to the 
event C observed by the DSC; D: Crystallization of cocrystal continues at 135°C after the 
melting of NCT; and E: Melting of cocrystal at 158°C. 
 
 
These thermal events confirm the thermal events observed in the DSC thermograms of 
CBZ/NCT mixtures in Figure 5.7.  Although a binary phase diagram is useful in the 
assessment of stability of cocrystals, however from the cocrystal and component fusion 
temperatures and enthalpies spontaneous cocrystal formation cannot be predicted, and the 
models presented here are useful to calculate the driving force for cocrystal formation.  
Similar analysis has been shown for racemic compounds, where the free energy of 





temperature between the racemic compound and its enantiomers.21  However, in some 
cases both racemic compounds as well as racemic conglomerates have been observed 
despite large differences in the melting point. 
 
Cocrystal Stoichiometry  
The DSC thermograms were used to analyze the cocrystal stoichiometry.  This 
was done by measuring the experimental heats of crystallization (∆Hcryst) for the 
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Figure 5.12: Enthaply of crystallization and melting of cocrystal at various concentrations 
of CBZ in the mixtures.   
 
Figure 5.12 shows the data for ∆Hcryst of cocrystal formation and enthalpy of fusion of 
cocrystal at various mole fractions of CBZ in the mixture.  Interestingly the greatest value 
of enthalpy of crystallization and fusion is observed at CBZ mole fraction of 0.5 





the mole fraction composition equivalent to cocrystal stoichiometry, both cocrystal 
components are available to their maximum concentration for reaction with the other 
component.  As the concentration of any one component falls, less cocrystal formation 
takes place as reflected in Figure 5.12.  Thus a careful analysis of the DSC thermograms 
might be useful in determining the cocrystal stoichiometry. The difference in the values 
of crystallization and fusion enthalpies of the mixture could be due to the embedded 
crystallization event occurring concurrently with melting resulting in an overall reduced 
observed heat of crystallization.  Rodríguez-Hornedo and Suryanaranayan have shown 
that cocrystals can be screened by thermal methods such as DSC27.  It is reported that a 
cocrystal can be anticipated if a eutectic melt is seen followed by the melting point of the 
cocrystal.  However a more careful analysis of the DSC thermograms is needed.  We 
address the examination of complex DSC thermograms using our studies with CBZ/NCT 
mixtures. Careful attention to the thermograms revealed 1st eutectic event occurs at 
108°C immediately followed by cocrystallization at 111°C. While the eutectic melt could 
still be observed for any binary mixture, it is not necessary that it would result in 
formation of a cocrystal or an addition compound.  We observe this behavior with 
CBZ/Citric acid mixture where there was no crystallization exotherm following the 
eutectic melt of the two components.  These thermal events should indeed be confirmed 
with additional testing using other complimentary methods such as variable temperature 








Experimentally accessible thermodynamic parameters can be utilized in 
determining the spontaneous cocrystal formation in the solid state. In the case when the 
free energy of formation largely depends on the difference of the fusion temperature 
between the higher melting component and the cocrystal. The data set analyzed suggests 
that for  to be negative, i.e., for spontaneous cocrystal formation to occur, the 
difference in the temperature between the higher melting component and the cocrystal 
must be approximately 45°C or less. In the case when the free energy would be negative 
if the sum of the fusion temperature of cocrystal components is less than 2.1 times the 
cocrystal melting temperature. The ideal entropy of mixing contributes toward the 
cocrystal formation. At any temperature T, below the MP of the lowest melting 
component, the cocrystal formation would be more favorable with the rise in temperature, 
as the contribution from the ideal entropy of mixing towards free energy of formation 
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       CHAPTER 6 
 
    CONCLUSION AND FUTURE WORK 
 
This dissertation has focused on the thermodynamic solubility and stability of 
pharmaceutical cocrystals. The specific goals of this dissertation were to (i) Investigate 
the role of coformer solubility influencing the cocrystal solubility and developing new 
cocrystals of lower solubility relative to the reference compound, (ii) Provide 
understanding on the role of lattice properties and solute-solvent interactions as 
parameters that govern the observed equilibrium solubility, (iii) Describe the pHmax for 
cocrystals and how this critical phenomenon can regulate the cocrystal solution stability.  
Lay out generalized guidelines that describe the parameters that affect the value of pHmax 
for cocrystals, (iv) Compare the solubility of cocrystals and salts and how cocrystals can 
offer solubility advantage over salts, (v) Importance of thermodynamic solubility 
measurements to access the true solubility of metastable cocrystals, by showing how 
kinetic solubility measurements of highly soluble solid forms could lead to 
misinterpretation of solubility due to phase transformation as well as the effect of 
common ions on such phase transitions, (vi) The role of surfactants is examined in the 
synthesis of cocrystals and how micellar concentration affects the solubility of a cocrystal 
of weakly basic drug and a non-ionic coformer, (vii) Thermal behavior of cocrystal 
components was studied by means of calorimetry and mechanism of cocrystal formation  
 
 
from the melt is presented.  Assuming ideality of a binary mixture, a phase diagram can 
be generated from a few experiments, yielding valuable information about the eutectics.  
(vii) Spontaneous cocrystal formation in solid mixtures was investigated and 
thermodynamic cycles were developed to estimate free energy of cocrystal formation 
from its reactants.  Several mathematical models were developed and presented in the 
research chapters for a robust understanding of cocrystal solid and solution phase 
chemistry and stability.   
The quest is not always about improving the solubility of a poorly soluble 
compound, but attaining the right solubility, which might involve lowering the solubility 
of a highly soluble compound due to its toxicity and for drug delivery.  Cocrystals allow 
us to tailor the drug solubility and dissolution kinetics and thereby facilitate the 
development of solid forms with customizable drug absorption and bioavailability 
profiles.  While a direct solubility measurement of thermodynamically stable cocrystals 
of gabapentin-lactam was possible as described in chapter 2, for high solubility cocrystal 
of lamotrigine, direct solubility measurement was not possible.  This is due to 
supersaturation and subsequent phase transformations to less soluble forms.  However, 
pH is an important factor in altering the thermodynamic solubility, such that beyond a 
critical pH value known as pHmax the thermodynamic stability of forms reverses and high 
solubility forms can be made stable.  This is investigated and presented in detail for both, 
(i) the relatively low solubility cocrystals of gabapentin-lactam, and (ii) for high 
solubility cocrystal of lamotrigine with nicotinamide as coformer.   pHmax is a eutectic 
point where in the three-component system (components A, B and solution) at constant 




(Gibbs phase rule).  One of the solid phases is the cocrystal while the other could be a 
cocrystal component or its solvate, different stoichiometry cocrystal, cocrystal solvate.  
Thus a eutectic point allows the measurement of the thermodynamic solubility of the 
cocrystal and to estimate the maximum stoichiometric solubility.  Analogous to salts, 
cocrystal are shown to exhibit pHmax and generalized models are derived to show the 
affect of Ksp, component solubility and ionization properties (pKa) on the value of pHmax.  
The advantage of these methods is that they are accessible and correspond to a 
thermodynamic equilibrium that is a reference point for describing solution phase 
behavior.  For a cocrystal of a non ionic compound with an acidic coformer, higher the 
value of drug solubility and coformer pKa, higher is the pHmax, while the cocrystal 
solubility (Ksp) is inversely proportional to the value of pHmax.  The contributions of 
fusion enthalpy and melting temperatures of several gabapentin-lactam cocrystals were 
compared to the experimentally measured solubility.  These correlations showed 
considerable deviations in the observed aqueous cocrystal solubility values from the ideal 
solubility behavior based on the contributions of crystal lattice alone.  For this small 
series of gabapentin-lactam cocrystals with weakly acidic coformers the key learning are 
(i) solvent-solute interactions quantified by activity coefficient, in water, were dominant 
relative to the ideal solubility estimated from fusion of the crystal lattice, (ii) solubilities 
increased exponentially when pH > pKa, while cocrystals with amphoteric coformer had 
U-shaped solubility-pH profile in accordance with coformer’s two pKa values, (iii) 
mathematical models provide a rational basis for selecting coformers to customize 
cocrystal solubility-pH behavior, (iv) solution pH can promote (or avoid) cocrystal 





is important toward expanding cocrystal-solubility relationships.  Future considerations 
of cocrystal solubility should seek to combine the observed solubility trends with the 
crystal lattice energy.  All gabapentin-lactam cocrystals studied in this dissertation have 
solubilities lower than both cocrystal components, this is a subject of further research 
where studying the crystal lattice properties would shed information as why the solubility 
is lower than both components.  Many cocrystals studied in the past have shown 
solubility values which is between that of its components.  Understanding these behaviors 
would enhance the rational selection of coformers as well as prediction of solubility 
behavior. 
In the case of lamotrigine-nicotinamide hydrate cocrystal discussed in chapter 3, 
the solubility of cocrystal is found to be 30 fold higher than that of lamotrigine hydrate.  
The estimation of this higher thermodynamic solubility relative to lamotrigine hydrate 
was possible by measuring the eutectic concentration of cocrystal components. 
Thermodynamic solubility of two cocrystals and two salts were compared with the 
reported solubility values determined by kinetic methods.  There is a large discrepancy in 
the reported solubility values which were determined by kinetic methods compared to the 
values obtained from the equilibrium methods presented in this thesis.  This is due to the 
solution phase mediated transformation of high solubility solid forms to more stable 
forms.  All solid forms studied transform to the lamotrigine hydrochloride salt since this 
salt has the lowest solubility and is the most stable form.  Cocrystal and salt solubility-pH 
dependencies revealed that experiments were in excellent agreement with those predicted 
by the solubility equations. The key leanings are, (i) By using the solid solution phase 





rationale experimental design to assess true solubility can be utilized, (ii) RCM was 
successfully used to synthesize lamotrigine-nicotinamide hydrate cocrystal.  Various 
methods presented in the literature were tried but did not result in a cocrystalline solid 
phase.  RCM with 2% SLS with NCT concentration above its eutectic concentration 
successfully generated pure cocrystalline phase, (iii) Critical stabilization concentration 
(CSC) was investigated in the presence of 2% SLS.  Although no CSC exists between 
lamotrigine-nicotinamide hydrate and lamotrigine hydrate, there is an approximately 8 
fold higher lamotrigine concentrations in 2% SLS solution.  This increase in the reactant 
concentration likely provides a conducive environment for cocrystal formation.  Future 
work should investigate the critical SLS concentration that is needed for cocrystallization 
as well as the mechanism by which SLS (micelles) aid in cocrystal formation.  This will 
expand the understanding of cocrystal formation via micellar solubilization and relate it 
to molecular structure and solubility differences of cocrystal components.   
 
 Spontaneous cocrystal formation in reactant mixtures was investigated and 
presented in chapter 4 of this dissertation, where physical mixtures of cocrystal reactants 
were prepared.  We hypothesized that if cocrystal formation is thermodynamically 
favored then cocrystal should form in simple physical mixtures without milling the 
reactants together.  Carbamazepine-nicotinamide and carbamazepine-saccharin cocrystals 
were tested and the factors that influence the kinetics were investigated.  Temperature, 
relative humidity as well as milling of individual reactants influence the cocrystallization 
rates.  Cocrystallization rates were higher when physical mixtures were stored at higher 
temperature, higher relative humidity and when prepared from individually milled 




in enhancing the kinetics of cocrystal formation.  When reactants were annealed after 
milling and prior to mixing, the rates of cocrystal formation were slower compared to 
milled and un-annealed reactants.  Other mechanism such as eutectic melt, deliquescence 
or vapor phase mediated cocrystal formation were not observed indicating that this was a 
solid to solid conversion of reactants to cocrystals.  Future work should investigate the 
role of reactant properties and mechanisms such as self catalysis, and progression of 
defects in the formation of cocrystals from solid reactants. 
 The driving force for cocrystal formation from solid reactants was modeled by 
developing thermodynamic cycles presented in chapter 5.   The thermodynamic cycles 
were used to derive the free energy expressions and estimating the sign and magnitude of 
free energy of formation of cocrystals.  From simple thermal parameters such as enthalpy 
of fusion (ΔHf), temperature of fusion (Tf), entropy of fusion (ΔSf) and mixing (ΔSm), 
heats of mixing (ΔHm) and heat capacities differences ΔCp, mathematical expressions for 
free energy of formation are derived.  Cocrystals were classified into two categories, one 
where the cocrystal melting point is between that of its components, and second where 
the cocrystal melting point is below that of its components.  Generalized equations were 
derived for both the classes of cocrystals and it was found that cocrystal melting point 
relative to that of its components is a key parameter that governs the sign and magnitude 
of molar free energy of formation ( ofG ). Unlike racemic compounds, cocrystal 
components are chemically different with different fusion temperatures and enthalpies.  
As a consequence the assumption applicable to racemates, that heat of mixing will be 
negligible would not hold for cocrystals and there can be significant contribution from 







free energies of formation of several cocrystals were calculated and it was found that 
higher the cocrystal melting point relative to its components more likely the value of 
 to be negative.  Future work should investigate a much larger sample of cocrystals 
and also include the contributions from heat capacity measurements, especially when the 
free energy of formation is close to zero.  A comparison of calculated and experimental 
evaluation of the enthalpy of mixing of cocrystal components would provide insights to 
the propensity of interaction between the components, which will enhance the accuracy 
of the models. 
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